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Para sa aking magulang at mga kapatid 
 
 
 Summary 
 
The ability of bacteria to evolve resistance to drugs has been recognized 
since the discovery of penicillin in the 1920s. Compounded by a slow novel an-
tibiotic development pipeline, the acquisition of resistance by pathogens is so 
prevalent and widespread that the loss of arguably the most important medical 
intervention of our period has become imminent. The challenge presented by 
the epidemic of resistance requires a clinically sufficient strategy that specifical-
ly delays the evolution of resistance to safeguard the future utility of our avail-
able drugs.  
In this dissertation, I approach the problem of resistance from the perspec-
tive of bacteria as they are exposed to drugs. I propose that the different re-
sponses both sensitive and resistant bacteria are able to produce during antibi-
otic treatment could help explain how resistance is maintained in the absence of 
selection, and could aid in the development of treatment strategies that dis-
courage the evolution of resistance.  
First, I aimed to describe the relationship between antibiotic concentration 
and the fitness of specific genotypes. I used a large set of sensitive and resistant 
bacteria and measured growth and death rates of all the strains in a wide range 
of drug concentrations. By doing so, I obtained fitness landscapes that were 
found to be strongly heterogeneous.  Combined with a mathematical model, the 
results produced in this chapter suggest that the strong dependence of bacterial 
fitness on specific antibiotic concentrations aids in the co-occurrence of both 
sensitive and resistant strains.  
In the following chapter, I describe a novel phenomenon that indicates a 
connection between resistant bacteria and the antibiotic to which they are re-
sistant. I find that growth of streptomycin resistant bacteria in high concentra-
tions of the drug produces transgenerational fitness benefits in the presence of a 
i
 second, unrelated drug. Revealing such effects impacts our understanding of 
resistance as more than just a mechanism by which bacteria survive treatment, 
but may also be adaptive in novel environments.  
Last, I consider combination therapy as a tool that could be applied to de-
lay the evolution of resistance. As an initial step towards the wider adoption of 
pairs of drugs in the treatment of acute bacterial infections, I show that a basic 
pharmacodynamic property of all antibiotics helps predict when an antagonis-
tic interaction can be expected. Manipulating different interactions between 
drugs has the potential to both increase clinical efficiency as well as control the 
problem of resistance.   
  
 
 Zusammenfassung 
 
Schon seit der Entdeckung des Penicillins in den zwanziger Jahren des 
letzten Jahrhunderts ist bekannt, dass Bakterien Resistenzen gegen Antibiotika 
entwickeln können. Aufgrund der Häufigkeit und der weiten Verbreitung von 
Antibiotikaresistenzen und weil die Entwicklung von neuen Antibiotika nur 
sehr langsam voranschreitet, droht die Gefahr, dass eine der wohl bedeutend-
sten medizinischen Errungenschaften bald wirkungslos wird. Angesichts dieser 
Entwicklung braucht es eine klinisch wirksame Strategie, die spezifisch darauf 
abzielt, die Evolution von Resistenzen zu verlangsamen, um die langfristige 
Wirksamkeit der vorhandenen Antibiotika zu garantieren. 
In dieser Dissertation untersuche ich, wie Bakterien während der Antibi-
otikabehandlung reagieren. Ich zeige auf, wie die unterschiedlichen Reaktionen 
von resistenten und sensitiven Bakterien zum einen dabei helfen können, zu 
verstehen, wie Resistenz auch ohne Selektion erhalten bleibt, und zum anderen 
zur Entwicklung von Strategien zur Verminderung der Resistenzevolution bei-
tragen könnten. 
Zuerst beschreibe ich den Zusammenhang zwischen der Konzentration 
von Antibiotika und der Fitness von spezifischen Genotypen. Ich habe die 
Wachstums- und Todesraten einer grossen Anzahl von sensitiven und resisten-
ten Bakterienstämmen innerhalb einer breite Spanne von Antibiotikakonzentra-
tionen gemessen. Die dabei erhaltenen Fitnesslandschaften stellten sich als sehr 
heterogen heraus. In Kombination mit einem mathematischen Model legen 
diese Resultate nahe, dass die starke Abhängigkeit der bakteriellen Fitness von 
der Konzentration des Antibiotikums das gemeinsame Auftreten von sensitiven 
und resistenten Bakterien ermöglichen kann. 
Das nächste Kapitel beschreibt ein neuartiges Phänomen, das eine 
spezifische Interaktion zwischen resistenten Bakterien und dem Antibiotikum, 
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 gegen das sie resistent sind, andeutet. Streptomycin-resistente Bakterien, die in 
einer hohen Konzentration des Antibiotikums wachsen, zeigen einen transgen-
erationellen Fitnesszuwachs, wenn sie in Gegenwart eines zweiten, nicht ver-
wandten Antibiotikums wachsen. Das Aufdecken solcher Zusammenhänge 
beeinflusst unser Verständnis von Resistenz als einem Mechanismus, der nicht 
nur das Überleben einer Antibiotikabehandlung ermöglicht, sondern auch eine 
adaptive Funktion in neuen Umgebungen hat. 
Im letzten Kapitel betrachte ich Kombinationstherapie als ein Instrument, 
das die Evolution von Antibiotikaresistenz verzögern könnte. Als erster Schritt 
in Richtung eines grossflächigeren Einsatzes von Paaren von Antibiotika für die 
Behandlung von akuten bakteriellen Infektionen zeige ich, dass eine grundsätz-
liche pharmakodynamische Eigenschaft aller Antibiotika vorherzusagen hilft, 
ob eine antagonistische Interaktion zwischen zwei Antibiotika erwartet werden 
kann. Durch die Manipulation der verschiedenartigen Interaktionen zwischen 
Antibiotika wird es unter Umständen möglich, sowohl die klinische Effizienz 
zu erhöhen als auch das Resistenzproblem unter Kontrolle zu bringen. 
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 Introduction 
Antibiotics are arguably the most important medical discovery in human 
history to date. Since the introduction of antibiotics to the clinic in the 1920s, in-
fections that were commonly fatal are now merely common and prophylactic 
antibiotic use has made modern surgery possible [1]. Bacteria, however, have 
kept pace with this innovation and have quickly evolved mechanisms to resist 
killing by every antibiotic shortly after each drug was made available to pa-
tients [2]. Now that the prolific drug discovery period of the 1940s to the 1960s 
has ended, the problem of antibiotic resistance has caught up and the risk of a 
pathogen becoming resistant to every drug available has become real [3].  
Laboratory studies of resistance have primarily and appropriately focused 
on the survivors of antibiotic exposure.  Identifying the mechanisms of re-
sistance bacteria employ has guided the search for new drugs and informed the 
design of completely synthetic antimicrobials [4,5]. Currently, every antibiotic 
on the market targets an essential function in bacteria. This is due to the princi-
pal role such mechanisms perform in facilitating normal bacterial physiology, 
as well as the high conservation across bacterial pathogens that increases the 
range of species susceptible to a drug that targets these processes [6]. These in-
clude classes of drugs that inhibit cell wall biosynthesis, ribosomal activity, and 
DNA replication and repair [7]. Individual drugs within each drug class may 
differ in terms of their potency, cellular bioavailability, range of susceptible bac-
terial species, associated adverse reactions, and even in the kind of resistance 
mechanism most commonly attributed to the drug. The repertoire of available 
antibiotics is in the hundreds [8]. However, considering the likelihood of re-
sistance and the needs of individual patients in terms of contraindications, the 
options for patients who harbor resistant pathogens shrink to a handful. It is 
important to note that resistance to the most widely used drug of last resort, 
vancomycin, is steadily increasing in frequency [9].  
1 
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 The crux of the antibiotic resistance epidemic we face today, in terms of its 
longevity and the speed of its spread, can be related to the fitness costs attribut-
ed to resistance. These costs are consistently among the most important factors 
that determine the rate and extent of the emergence of resistance [10–12]. The 
cellular machinery responsible for essential bacterial functions have evolved 
over millennia and while resistance mutations on these genes may allow for 
continued growth in the presence of an antibiotic, a variety of fitness costs often 
manifest when drug is withdrawn. These include reductions in growth rate or 
virulence, or in increased clearance rates [13]. It was assumed, therefore, that 
the absence of selection would disfavor the maintenance of costly resistance. 
This has clearly not been the case and is exemplified by the increasing rise in 
community-acquired resistant infections [14–16]. This troubling statistic sug-
gests that resistance determinants are readily acquired in areas where drug use 
is limited, and the bacteria that carry these genes or mutations are able to com-
pete effectively against environmental strains. A reevaluation of our under-
standing of antibiotic resistance and the fitness deficits this may entail is over-
due.  
 
The problem of resistance from the perspective of bacteria undergoing anti-
biotic exposure  
In this dissertation, I argue that broadening the frame of study to include 
the responses of bacteria during antibiotic treatment can help explain different 
facets of the problem of antibiotic resistance.  Specifically, I suggest that the 
presence of antibiotics is an important though currently overlooked context in 
which to measure bacterial fitness and document bacterial responses. In the first 
two research chapters, I address aspects that contribute to the magnitude and 
urgency of the problem of resistance. I provide evidence that suggests a role for 
antibiotic exposure in maintaining resistance as well as proposing a means in 
which resistant bacteria treated with antibiotics can be favored in the presence 
of a second, unrelated antibiotic. Last, I consider novel treatment strategies 
aimed at reducing the probability of resistance and demonstrate how an under-
standing of the responses of bacteria to antibiotics is a crucial first step in de-
veloping clinically effective and sustainable therapeutic regimes.  
As a framework for the entire dissertation, here I review the mechanisms 
of resistance and resistance acquisition, how this relates to fitness costs, and 
importantly how environment affects fitness. Second, I examine facets of the 
problem of resistance that I contend are best approached from the perspective 
of bacteria as they endure and respond to antibiotic therapy. These aspects are 
then addressed in the subsequent research chapters. 
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 Mechanistic links between antibiotic resistance, fitness costs, and environ-
mental context 
The first distinction that needs to be made is to separate resistance deter-
minants into chromosomal mutations that alter the targets of antibiotics, and 
dedicated resistance genes that are usually carried by accessory elements. The 
second category primarily consists of enzymes that specifically degrade or 
modify antibiotics, or pumps that remove the antibiotic from the cell.  
In Chapters 2 and 3, I employ S. enterica and E. coli bearing mutations on 
rpsL, which grants resistance to streptomycin. This drug binds to the 16S rRNA 
of the 30S ribosomal subunit and induces codon misreading [17]. Although the 
clinical utility of this antibiotic is limited due to the intravenous mode of deliv-
ery required, the variety of mutations and the associated costs and characteris-
tics these mutations impart on bacteria has established streptomycin as a cor-
nerstone of many laboratory studies. Numerous mutations on rpsL, the gene 
that encodes the highly conserved S12 protein of the ribosomal accuracy center, 
lead to resistance to streptomycin [18]. The diversity of effects of mutations on 
rpsL ranges from no costs on fitness, severe reductions in fitness in vitro and in 
mice, and even dependency on the presence of the drug for growth [19]. As a 
concrete illustration of the relationship between resistance and cost, in some 
cases the mechanism of resistance and the mechanism underlying the fitness 
cost are the same. The codon misreading produced by streptomycin can be cor-
rected by so-called restrictive rpsL mutations; this sub-group of mutations in-
creases the rate of proofreading and translational accuracy at the expense of de-
creasing protein elongation rates [20]. Irrespective of the mechanism of action of 
an antibiotic, the majority of studies report fitness costs associated to resistance 
caused by a mutation to the target of a drug [21].   
While resistance determinants carried on extra-chromosomal elements 
such as plasmids do not involve changes to essential cellular machinery, a 
number of studies have similarly reported fitness costs associated with the car-
riage of plasmids [22]. The plasmid itself may result in a cost to the cell via the 
metabolic burden it imposes through it’s maintenance and duplication during 
every cell division event [23]. The expression of dedicated resistance enzymes 
may impose some energetic cost, and efflux pumps may increase the permeabil-
ity of the cell wall leading to the leakage of cellular components [24]. Currently 
however, it is not certain how common these costs are and how they may 
change across different combinations of plasmids and hosts. Furthermore, regu-
latory systems encoded in the plasmid may help limit the expression of these 
genes thus reducing costs in the absence of drug [25]. Finally, instead of amelio-
rating the costs of a resistance element carried by a plasmid to favor the 
maintenance of this trait, plasmids often have mechanisms that ensure their 
faithful transmission to each daughter cell during cell division [26]. As a conse-
quence, the mechanisms that aid the transmission of plasmids indirectly aid the 
maintenance of the genes carried on the plasmid. In addition, the problem of 
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 resistance is exacerbated by the ability of some plasmids to infect many differ-
ent bacterial species. This could lead to the swift dissemination of resistance 
across a particular bacterial population, and even across diverse bacterial com-
munities.  
Regardless of the location of a resistance determinant, either on the chro-
mosome or on an accessory element, an increasing number of studies highlight 
the importance of environment in exposing costs to resistance. The costs of nor-
floxacin resistance in E. coli, the most common causative agent of urinary tract 
infections, varies depending on whether fitness is measured in vitro, in urine, or 
in a mouse [27]. Furthermore, the relationship between environment and re-
sistance may have unexpected effects besides modifying fitness costs due to re-
sistance. Environmental changes may even facilitate the evolution of resistance, 
as when E. coli evolved in high temperatures but in the absence of any antibiotic 
consistently acquired resistance mutations to rifampin [28]. The opposite has 
also been observed with environment constraining the evolutionary trajectory 
of bacteria. While bacteria containing a costly fusidic acid resistance (FusR) mu-
tation passaged in rich media were able to acquire secondary mutations that 
alleviated their fitness loss (see Chapter 2 for more on second-site compensato-
ry mutations), this was not observed in the same bacteria passaged in mice. 
Mechanistically, this is believed to be caused by the altered levels of the nucleo-
tides (p)ppGpp in FusR mutants [29]. These nucleotides are pleiotropic regula-
tors of gene expression and changes in their concentration affect virulence 
genes, which in turn influences the fitness of FusR bacteria in mice [30]. Finally, 
the environmental context in which bacteria are observed has been shown to 
have clear clinical implications. Some types of colistin resistance in the hospital-
acquired pathogen, Acinetobacter baumanii, only become detectable when the 
environmental growth conditions of the clinical assay are altered [31]. A range 
of growth conditions are necessary to not just accurately describe the costs of 
resistance but in some cases even reveal the presence of resistance.  
In the following two chapters, my experiments employ chromosomal mu-
tations for their strong and varied fitness costs. I take an under appreciated per-
spective and consider the effect of antibiotics on the fitness of resistant bacteria. 
This is an integration of two well-studied ideas: since resistance mutations are 
often costly and the costs of resistance can vary depending on environment, one 
would expect that an antibiotic-containing environment may affect the fitness 
or responses of bacteria resistant to that antibiotic. The results I present in the 
proceeding chapters demonstrate how this perspective adds to our understand-
ing of resistance - how it is maintained, how it may extend in scope, and how 
the effects in the presence of an antibiotic may even be harnessed to inform the 
choices we make in the clinic.  
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 Maintenance of costly antibiotic resistance 
Although antibiotic resistance in human pathogens was first recognized 
shortly after antibiotics had been put to use in medical settings, there are still 
basic aspects of this problem that we do not fully understand [2]. This gap in 
our conception is exemplified in our insufficient attempts at devising strategies 
that can reverse the evolution of resistance or even control its spread. In seeking 
to achieve both of these goals, studies have focused on the disparity in fitness of 
resistant genotypes in the presence and absence of drug selection. Since antibi-
otic treatment would without question favor resistant over sensitive bacteria, 
the opposite scenario was similarly the expected outcome; a reduction in anti-
biotic usage was thought to favor replacement of resistant by sensitive bacteria 
[32]. The rise of resistant pathogens in areas where antibiotic use is limited has 
lead to an adjustment in our perception of the conditions in which resistance 
emerges and is maintained [14]. Studies aimed at explaining this result have fo-
cused on the genetic mechanisms by which bacteria reduce fitness costs due to 
resistance in order to remain competitive against sensitive bacteria, and more 
recently whether and how different environments may affect this competition 
[30,33]. One such important environmental factor is clearly the presence or ab-
sence of an antibiotic, but also the effect of varying antibiotic concentrations.  
A direct test of the hypothesis that withdrawing an antibiotic would ex-
pose the fitness difference between sensitive and resistant bacteria and would 
thus negatively impact the maintenance of resistance was performed in an en-
tire county in Sweden from 2004 until 2006 [34]. The folate synthesis inhibitor 
trimethoprim was voluntarily discontinued, replaced with an appropriate al-
ternative, and resistance was monitored in Escherichia coli isolated from urinary 
tract infections. Although trimethoprim-containing drug use dropped by 85%, 
no appreciable effect on the frequency of resistance was reported. Laboratory 
experiments suggested that a lack of detectable costs as well as strong co-
selection by other antibiotics were responsible for this disappointing result.  
Although it is clear that therapeutic levels of drug quickly select for re-
sistance, the role of low antibiotic concentrations that are present in many envi-
ronments has only recently been studied. Using highly sensitive competition 
assays, Gullberg and colleagues demonstrate how selection for resistance could 
occur in antibiotics several hundred-fold below the minimal inhibitory concen-
tration [35]. They show that while the deleterious effects on susceptible bacteria 
in very low antibiotic levels may be slight, the disparity this creates between the 
fitness of sensitive and resistant genotypes is nevertheless sufficient to favor re-
sistant bacteria.  
While the competition between resistant and sensitive bacteria can be af-
fected by small changes in fitness induced by sub-inhibitory amounts of antibi-
otic, little attention has been paid to how antibiotics may influence competition 
among only resistant bacteria. Depending on the resistance determinants they 
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 carry, these bacteria will express varying degrees of fitness, virulence, and sus-
ceptibility to antibiotics. Depending on their genetic background, resistant bac-
teria may even vary in their probability of reverting back to an antibiotic sus-
ceptible genotype.  
In Chapter 2, my collaborators and I ask how antibiotic concentration and 
secondary mutations may affect the fitness of sensitive and resistant bacteria, 
and whether this interplay can predict the likelihood of reversion. The second 
site mutations we assess are a commonly recognized but poorly understood 
mechanism by which pathogens are thought to modulate costly resistance. In-
stead of losing the mutation responsible for resistance, numerous laboratory 
studies have shown that bacteria are more likely to acquire a second-site muta-
tion that is only beneficial in the presence of the resistance mutation [36–40]. In 
this chapter, we probe the relationship between fitness and drug concentration 
by creating fitness landscapes of sensitive and resistant bacteria to determine 
whether combinations of drug levels and mutations may lead towards rever-
sion.  
 
Genetic and environmental interactions that aid the spread of resistance  
The costs of resistance play a central role in determining whether re-
sistance is maintained, spreads, or is lost [41,42]. The rise of multidrug resistant 
and even extensively drug resistant tuberculosis suggests that bacteria are able 
to modify these costs, or survive despite these costs [43,44]. Understanding the 
process by which bacteria acquire and retain not just one but many costly re-
sistance elements is necessary in addressing and preventing the challenging in-
fections we already face. 
A specific resistance mutation may impose a range of costs dependent on 
the genomic context. These fitness effects may vary in strength or even form 
contingent on the presence of other mutations, including a second resistance 
allele. Using Escherichia coli transduced to carry pairs of different mutations, 
Trindade and colleagues performed competition assays in the absence of drug 
to measure epistasis between resistance determinants [45]. Besides the perva-
sive positive epistasis they find between resistance alleles with respect to fitness 
in the absence of drug, they also report that some cases of double resistance 
produce no measurable cost or are even beneficial when combined. Altering the 
deleterious effect of single resistance mutations with a second resistance allele 
provides a possible explanation for why multidrug resistance is so widespread 
and why its eradication is so difficult. 
Aside from mutations, one study has implicated the environment in ame-
liorating the costs of deleterious mutations. Slow growing bacteria created via 
random mutagenesis were grown in the presence and absence of different 
stressors to determine whether such environments could reduce the average 
cost of a deleterious mutation [46]. Researchers used a variety of conditions 
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 ranging from osmotic pressure to low temperature, including low concentra-
tions of antibiotics. In contrast to the perception that carrying a deleterious mu-
tation reduces an organism’s tolerance to stress, they find certain environments 
that on average alleviate the cost of random deleterious mutations.  
Medically important bacteria, both pathogens and commensals, navigate 
environments in which they are exposed to a large range of antibiotics and an-
tibiotic concentrations. These include their time within a human host in which 
drug penetration and first-pass metabolism will create patches of low and high 
drug, and as they travel between hosts such as in hospitals where antibiotics are 
in abundant supply. In Chapter 3, I ask whether environments containing sub-
inhibitory antibiotic concentrations may alleviate the cost of a resistance muta-
tion to a second antibiotic. In the course of addressing this question, I find sur-
prising results that indicate how growing resistant bacteria in the antibiotic to 
which it is resistant will affect its future success in a second drug. These find-
ings have implications on how antibiotic pollution may promote the mainte-
nance of costly resistance, and also induce a range of responses only available 
to resistant bacteria.  
 
Manipulating cellular responses to antibiotics  
Our nearly 100 years of experience using antibiotics in the clinic has 
shown repeatedly that pathogenic bacteria will evolve resistance to the drugs 
we discover or develop. This observation, however, has not changed the ap-
proach the scientific and medical communities advocate in tackling bacterial 
resistance. Although new molecules such as biofilm or virulence determinants 
are being recommended as targets for novel antimicrobials, history suggests 
that revitalizing the antibiotic pipeline is only a temporary solution [4,47,48]. 
The ease at which bacteria acquire, maintain, and even diversify their resistance 
arsenal demands a solution that combines novel drug discovery with sustaina-
ble drug policies that aim to delay the evolution of resistance and lengthen the 
useful life of our available antibiotics.  
The gold standards in the treatment of the most widespread chronic infec-
tious diseases of our period, HIV and tuberculosis, explicitly consider the pre-
vention of resistance in their rationale [49,50].  In both examples, using combi-
nations of drugs has been shown to effectively delay resistance. For these dis-
eases, the chronic nature of the infection demands a sustained treatment dura-
tion. This increases the opportunity of the pathogen to evolve resistance. Most 
bacterial infections, however, are acute and drugs are prescribed for only a few 
days. Treatment failure due to resistance is not yet a concern in devising antibi-
otic dosing strategies.   
Though there are a few cases of acute bacterial infections for which com-
bination therapy is recommended, the underlying reasoning for their usage is 
to exploit a synergistic interaction between antibiotics [51]. These specific pairs 
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 of drugs together have been proven to produce an effect greater than the com-
bination of their individual effects. Aside from synergy, pairs of drugs may also 
interact in opposition with each other and such antagonistic interactions have 
been shown to result in treatment failure [52–54].  
The two principles of resistance prevention or drug synergism that form 
the basis of combination therapy in chronic or acute infections are not in oppo-
sition to each other. The range of demonstrated benefits already attributed to 
combination therapy suggests that a reappraisal of this strategy towards the 
treatment of a larger number of bacterial infections has the potential to both ef-
fectively treat patients as well as delay the emergence of resistance.  
As a first step towards the wider usage of combination therapy, in Chap-
ter 4 I propose a simple explanation for when certain antibiotic pairs would re-
sult in an antagonistic interaction. I hypothesize that a basic pharmacodynamic 
property of all drugs is a useful aid in predicting when a specific combination 
will result in antagonism. Since the killing effect of bactericidal drugs is poten-
tiated by active bacterial growth, we rationalize that these drugs would be an-
tagonized by the simultaneous application of an antibiotic that induces cell sta-
sis. We perform a screen of pairwise interactions among more than 20 different 
antibiotics and find that a vast majority of antagonistic pairs are composed of a 
bactericidal and a bacteriostatic drug. We confirm these findings for a subset of 
these combinations on the population level using time kill curves and on the 
single cell level using a microfluidic device. We provide direct visual and quan-
titative information on how the induction of cellular stasis leads to the survival 
of a population exposed to inhibitory drug concentrations. Our results demon-
strate how observations of bacterial responses to drugs could aid in the design 
of new treatment strategies.  
 
Insight into the problem of resistance from the perspective of bacteria ex-
posed to antibiotics 
Determining the resistance mechanisms of pathogens has lead to tangible 
changes in how bacterial infections are treated. Among the oldest of the drugs 
still in use today, antibiotics of the beta-lactam class are still valuable due to 
such work. One of the most common mechanisms of resistance bacteria have 
evolved against beta-lactams is beta-lactamase [7].  This enzyme directly de-
grades members of the penicillin, cephamycin, and carbapenem families. These 
antibiotics remain effective, however, due to the development and inclusion of 
beta-lactamase inhibitors in the same drug preparation as their beta-lactam 
partners [55]. The discovery of beta-lactamase inhibitors also guided the design 
of methicillin, a penicillin antibiotic insensitive to penicillinase. Unsurprisingly, 
the continued utility of these drugs has come into question due to the emer-
gence of resistance to beta-lactamase inhibitors and to methicillin [56].  
8
 Pathogenic bacteria have consistently and quickly evolved resistance to 
every drug employed in clinics, suggesting that novel drug design alone is only 
a shortsighted response to the problem of antibiotic resistance. Although this 
strategy has not proven to be sustainable, biomedical researchers and econo-
mists are clamoring for changes in policies from governments to address the 
problem of resistance by revitalizing the antibiotic pipeline [57,58]. They argue 
that a combination of tax incentives and advance purchase contracts would sus-
tain the research and production of antibiotics to maintain our lead in treating 
patients with resistant infections. It is not disputed that new drugs are sorely 
needed, however this solution alone would only strengthen our dependence on 
continuous drug development. The widening scope and increasing incidence of 
resistant infections suggests that the manner in which antibiotics are prescribed 
must be reassessed to safeguard the needs of patients, slow the evolution of re-
sistance, and extend the useful life of the drugs we have.  
In this dissertation, I argue that broadening the focus of study to include 
how both sensitive and resistant bacteria respond to a range of antibiotic con-
centrations will provide new insights into an established, enduring, and in-
creasing problem. As resistance has spread from the hospital to include the 
community, our concept of when and how resistance emerges and is main-
tained must be similarly readjusted. In order to maintain our lead over con-
stantly evolving pathogens, solutions to the problem of antibiotic resistance 
cannot rely solely on the development of new drugs. Close attention must be 
paid on how and to what extent antibiotics are deployed in treatment and in the 
environment to delay the spread of resistance and preserve our ability to treat 
bacterial infections. 
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 Abstract 
The increasing incidence of resistant infections suggests that bacteria are 
able to maintain their often costly resistance mutations even when antibiotic us-
age is low. Understanding the mechanisms by which bacteria reduce these fit-
ness costs is a crucial first step in devising strategies to slow the progression 
and address the possibility of reversing the evolution of resistance. The acquisi-
tion of a compensatory mutation, a second-site mutation that is beneficial in the 
presence of a resistance mutation but is otherwise deleterious, is one means in 
which bacteria are thought to alleviate the cost of resistance and to disfavor re-
version to a sensitive state. Our current understanding of the effects of these 
mutations is hampered by a lack of quantitative observations.  In this study, we 
sought to clarify the influence of compensatory mutations in maintaining costly 
resistance by obtaining drug-dependent fitness landscapes involving different 
compensatory mutations. We employed a set of S. enterica serovar typhimurium 
strains consisting of one sensitive and one streptomycin resistant genotype, 17 
variants of the resistant strain each bearing one specific compensatory muta-
tion, and the corresponding sensitive genotypes each bearing the same com-
pensatory mutations. The measurements of growth and death rates we per-
formed across a large range of antibiotic concentrations described landscapes 
that are characterized by a strong dependence on antibiotic concentration. We 
find that the relative fitness of compensatory mutations in a susceptible and re-
sistant strain background strongly depends on drug concentration. For some 
concentrations, compensatory mutations increase the fitness of both sensitive 
and resistant bacteria. We drew on these results to model the evolutionary dy-
namics of these genotypes as they undergo antibiotic treatment. The range of 
effects we observed across different alleles in different drug concentrations led 
to scenarios in which both resistant and sensitive genotypes co-occur.  
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 Introduction 
The problem of antibiotic resistance is characterized not only by the ease 
at which resistance determinants are acquired, or the frequency at which multi-
drug resistance is observed, but also by the duration in which resistance per-
sists after drug use is discontinued. The troubling rise in resistant infections 
suggests that there are gaps in our understanding of antibiotic resistance [1–3]. 
The acquisition of resistance is often associated with fitness costs to the bacteria; 
these can manifest as reductions in growth rate or virulence, or increased rates 
of clearance of the infection [4–6]. This disparity in fitness between resistant and 
sensitive bacteria predicts that the discontinuation of a drug would cause a re-
duction in the incidence of resistant infections. Numerous experimental studies 
testing this hypothesis instead observed the acquisition of compensatory muta-
tions, second-site mutations that alleviates the cost of resistance but are delete-
rious on their own [7–12].Compensatory mutations may create a local fitness 
peak with a fitness valley between the compensated resistant and the sensitive 
genotype, which is then assumed to prevent or slow down reversion to suscep-
tibility in the absence of drug.   
In order to properly assess the influence of compensatory mutations in 
maintaining costly resistance, it is first required to determine the conditions 
under which such fitness peaks are created. Only one laboratory study has 
measured the effects of these mutations in both the presence and absence of 
drug [13]. They find that compensatory mutations selected when treatment is 
withdrawn only increase fitness in a drug-free environment. Furthermore, alt-
hough specific compensatory mutations to an assortment of antibiotic resistance 
mutations have been identified, no study has measured the fitness effects of 
compensatory mutations in a sensitive strain background.  
Obtaining such information may help explain the divergent clinical results 
– while laboratory experiments consistently cite compensatory mutations as 
barriers to reversion, evidence from patients is inconsistent and inconclusive 
regarding the influence of these mutations [12]. Reversion may also be more fa-
vorable in vivo than in vitro as indicated by a number of reports from individual 
patients [4,14–16].  
Recently, theoretical studies have sought to reconcile the contrasting re-
ports from the lab bench and from patients. Attempts at bridging this gap have 
considered the possibility of differential fitness effects in the presence and ab-
sence of drug, or the effect of fluctuating environments on determining reversi-
bility [17,18]. Compensatory mutations have the potential to strongly influence 
the evolution and maintenance of resistance. A more complete grasp of their 
fitness effects is required to accurately assess their importance and devise strat-
egies to prevent their acquisition.  
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 In this study, we contribute to the understanding of compensatory muta-
tions by measuring the fitness effects as growth or death rates of all the relevant 
genotypes across a wide antibiotic concentration range. The set of strains we 
employ are described in [9]. In brief, the study in which the strains were pro-
duced sought to determine the diversity of mutations that can compensate for a 
specific resistance mutation to streptomycin. They considered the K42N substi-
tution on rpsL, which increases the rate of ribosomal proofreading leading to 
decreased bacterial growth and decreased virulence in Salmonella enterica 
serovar typhimurium. They serially passaged 81 independent lines of this mu-
tant in the absence of antibiotic until fitness was observed to increase. Four lines 
were found to have regained fitness by losing the resistance mutation, however 
the 77 other lines remained streptomycin resistant and contained at least 35 dif-
ferent amino acid substitutions that did not appear during passage of sensitive 
control lines. These 35 second-site mutations as well as the original resistance 
mutation were separated and then combined again using P22-mediated trans-
duction. The results we present are based on half of the set of strains they con-
structed.  
Our study population consists of the sensitive S. enterica serovar typhi-
murium strain (denoted ++) and the streptomycin resistant version (R+), 17 re-
sistant strains each bearing a specific compensatory mutation (RC), and the 17 
corresponding sensitive strains (+C). We use our estimates of growth or death 
rates to describe fitness landscapes in the absence of drug and then extend our 
exploration from very low to high drug concentrations to determine the effects 
these environments may have in shaping a genotype’s fitness. We apply our 
experimental results to simulations of the evolutionary dynamics of these 
strains as antibiotic therapy is applied and subsequently removed. In this fash-
ion, our model determines the effect of compensatory mutations on the mainte-
nance of costly antibiotic resistance and the likelihood of reversion to a sensitive 
genotype.  
 
Results  
Increasing drug concentration produces diverse effects on fitness landscapes  
Figure 1 depicts three plots, each showing the fitness measurements of a 
different pair of RC and +C strains along with the ancestral sensitive and re-
sistant (++ and R+) across the entire range of antibiotic concentration consid-
ered in this study. Supplementary Figure 1 presents the entire set of dose-
response curves.  
The dose-response curves we obtained are highly heterogeneous and are 
strongly dependent on antibiotic concentration. There are conditions in which 
sensitive strains become less fit as drug increases, however the converse re-
sponse is also evident - in all strains, across both sensitive and resistant geno-
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 types, we find areas of drug concentration in which growth rate increases as an-
tibiotic dosage also increases. An example of this is illustrated in the middle 
panel of Figure 1, where the red line represents the fitness estimates for the RC 
strain bearing the C mutation, rpsE T130I. As streptomycin concentration in-
creases from 5 to 10 ug/mL, the fitness of this strain increases significantly (un-
paired, two-tailed t-test assuming unequal variance, p = 0.0004). However a fur-
ther increase in concentration from 10 to 15 ug/mL results in a significant de-
crease in fitness (unpaired, two-tailed t-test assuming unequal variance, p = 
0.0001).  
These effects are also allele specific as different compensatory mutations in 
the same locus can produce significantly different growth or death measure-
ments. As an example, consider an RC strain that contains either the rpsD N84D 
or N84S compensatory mutations (Refer to panels Compensatory Allele #3 and 
Compensatory Allele #4 in Supplementary Figure 1). The fitness of these two 
RC strains do not differ significantly at 1000 ug/mL, however raising the drug 
concentration to 10,000 ug/mL results in a significant drop in fitness of the 
N84S strain in comparison to N84D (unpaired, two-tailed t-test assuming une-
qual variance, p < 10-8).  
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Figure 1. Dose-response curves of three sets of streptomycin-sensitive (++), 
streptomycin-resistant (R+), resistant and compensated (RC), and the corre-
sponding sensitive and compensated genotypes (+C). 
These plots depict the growth rates of a set of four genotypes across a range of 
streptomycin drug concentrations. To allow for a clearer comparison of the geno-
types, the ancestral sensitive and resistant strains are shown along with the fit-
ness effects of sensitive and resistant variants bearing compensatory allele #2, al-
lele #15, and allele #17 in the lowest graph. Closed circles denote the mean of 
eight replicates (open circles).  
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As the original experimental conditions selected for mutations to emerge 
in a resistant strain in the absence of drug, we observed all RC strains to have 
higher fitness than R+ when there is no drug present. However, we found that 
the presence of these compensatory mutations can either increase or decrease 
the fitness of a resistant strain in the presence of drug. As an overview, Figure 
2A plots the relative fitness differences between R+ and RC strains across every 
drug concentration measured. The boxplots above the 0 line denote the fitness 
advantage of RC over R+ strains as it extends across the range of drug concen-
trations measured, until the highest drug concentration where this situation re-
verses and RC strains had significantly lower growth rates than R+ (unpaired, 
two-tailed t-test assuming unequal variance, p < 10-10).  
The effects of the C mutations on the fitness of a sensitive strain span a 
wider range.  In the absence of antibiotic and of the resistance mutation, some 
second-site mutations are deleterious while others displayed little to no cost, or 
even increase fitness. Interestingly, these effects segregate according to the gene 
of the C mutation. +C strains bearing mutations on rpsD were significantly less 
fit than ++ in the absence of drug (unpaired, two-tailed t-test assuming unequal 
variance, p < 10-5), while C mutations on rpsE or rplS did not significantly affect 
fitness compared to the ancestral sensitive strain.  
Our measurements of the effects of compensatory mutations on sensitive 
and resistant genomic backgrounds confirms that the combination of effects of 
mutation and dosage results in an RC strain being the most fit for a wide range 
of drug concentrations. The diversity of the effects we observed, however, rais-
es the possibility that specific dosage and mutation combinations can disfavor 
the maintenance of resistance. This relationship between concentration and fit-
ness may affect the widely acknowledged role of compensatory mutations in 
maintaining resistance in the absence of selection. Bergstrom and Feldgarden 
have described this effect as an “evolutionary lobster trap” [19]. They defined 
this process as a genotype easily accessible under selection in one direction, but 
difficult to leave when selection goes in the other direction. In the case of anti-
biotic resistance, a bacterial strain enters this trap if it acquires a compensatory 
mutation that is beneficial in the resistant strain background but is deleterious 
without the resistance allele.  
Figure 2B shows how dosage can influence these fitness effects as the dis-
tribution of the relative magnitude of the lobster trap created by the compensa-
tory mutations. Specifically, this graph plots the distribution of the relative fit-
ness differences between each RC against the most fit sensitive partner, either 
the ++ or the corresponding +C. Positive values denote the beneficial effect of 
the compensatory mutation in a resistant background and the presence of a lob-
ster trap situation – under that particular condition, reversion to sensitivity is 
disfavored. Negative values, however, suggest the opposite and this is ob-
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 served at very high antibiotic concentrations, as well as for some cases at sub-
inhibitory concentrations.  
Finally, Figure 2C extracts from each set of four strains (i.e., 17 sets of ++, 
R+, RC, and +C, differing by the 17 specific C mutations) which genotype is fit-
test at each concentration. The mixture of R+ and RC at high concentrations and 
++, +C, and even RC in the absence of drug reiterates the range of fitness effects 
imparted by compensatory mutations originally selected in the absence of drug.  
 
Whole Genome Sequencing 
In order to corroborate the unexpected experimental results we obtained, 
whole genome sequencing was performed on the ++ and four +C strains to de-
termine whether the fitness effects we observed could be due to other genetic 
changes aside from the introduced C mutations. The sequencing results re-
vealed that the ++ and +C strains only differ by their respective C mutation.  
 
Model results strongly depend on drug concentration 
We applied our fitness measurements to model the in vivo dynamics of a 
bacterial population subjected to five days of streptomycin therapy at a clinical-
ly relevant concentration, followed by three months without antibiotics (Figure 
3A). We were interested in determining whether sensitive genotypes could be 
detected under such conditions. We modeled 17 scenarios separately and allow 
for mutations, both resistance and a single compensatory mutation, to evolve 
and affect the population dynamics of the four emerging genotypes. Figure 3B 
depicts the population dynamics we observed for strains permitted to acquire 
allele #17. Finally, Figure 3C presents the average composition of the bacterial 
population for all 17 scenarios after the treatment and withdrawal periods.  
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Figure 2. Distributions of relative fitness effects of compensatory mutations.  
A. The distribution of relative fitness differences between R+ and RC ((wRC – 
wR)/wRC) across concentrations indicates the antibiotic conditions in which 
bearing a compensatory mutation is beneficial (positive values) and in which 
compensatory mutations incur fitness costs.  
B. Compensatory mutations may “trap” the resistant genotype on a fitness peak. 
This distribution of the relative magnitude of this trap ((wRC – 
max(wR+,w+C))/wRC) reveals the conditions in which such a situation is pre-
sent (positive values).  
C. Plotting the proportions of the four genotypes in increasing drug concentration 
according to their fitness reveals the heterogeneous effects of compensatory mu-
tations – some can be beneficial in the absence of drug and the majority are dele-
terious at high drug concentrations.  
0 0.5 2.5 5 10 15 20 40 60 80 100 1000 10000
-4
0
-2
0
0
20
40
concentration [mg/L]
%
 fi
tn
es
s 
di
ffe
re
nc
e
0 0.5 2.5 5 10 15 20 40 60 80 100 1000 10000
-4
0
-2
0
0
20
40
concentration [mg/L]
%
 fi
tn
es
s 
di
ffe
re
nc
e
0 0.5 2.5 5 10 15 20 40 60 80 100 1000 10000
concentration [mg/L]
%
 o
f C
 m
ut
at
io
ns
0
20
40
60
80
10
0 ++ R+ +C RC
A.
B.
C.
24
  
Figure 3. Model Results  
A. Pharmacodynamics of the streptomycin treatment regime applied in the mod-
el. The sensitive ++ strain is exposed to a pulse of streptomycin reaching a maxi-
mum concentration of 40 ug/mL for 7 days, during which the resistance muta-
tion as well as one specific compensatory mutation may evolve. Drug is then 
withdrawn and the emerging populations compete and are observed for an addi-
tional three months. This simulation is performed for each of the 17 different sets 
of RC, +C pairs.   
B. Population dynamics of strains allowed to acquire compensatory allele #17.  
C. Average composition of strain types for each of the 17 sets of four genotypes at 
the end of the simulation.  
D. To facilitate comparison, the relative fitness of all the genotypes to the ++ in 
the absence of drug is presented.  
25
 Simulations suggest compensatory mutations aid in the co-occurrence of re-
sistant and sensitive genotypes. 
Our simulations provide evidence for a role of compensatory mutations in 
maintaining costly resistance in the absence of antibiotic selection – as well as 
favoring the reemergence of sensitive genotypes. Although our theoretical 
study yielded a wide variety of outcomes, the co-occurrence of sensitive and 
resistant bacteria was consistent for all 17 compensatory mutations.  
The variety in the results we observed is striking and some results in par-
ticular stand out. For example, though resistant genotypes are the most abun-
dant in every situation, this is not always the RC strain – for some cases, the R+ 
strain is present at equal or even higher proportions. Similarly, while sensitive 
genotypes are always present at the end of the observation period, there are 
cases in which the +C comprises a larger fraction of the population than the ++.  
 
Simulations underline the importance of fitness measurements performed 
across drug concentrations 
We observed that integrating the fitness measurements across a wide 
range of drug concentrations had profound effects on the population dynamics 
of resistant and sensitive bacteria in our simulation. Without these fitness land-
scapes, predictions would be made relying solely on fitness data in the absence 
of drug (Figure 3D). Comparing Figures 3C and 3D, we found cases in which 
the fitness measurements could not be used to estimate the simulation results. 
For example, the +C and RC strains of allele #3 display similar fitness meas-
urements in the absence of drug (Figure 3D). In contrast, our model predicts 
that the RC would outcompete the +C (Figure 3C).  
We next focused on the effect of antibiotic decay in influencing the results 
of the model. The pharmacokinetics of an antibiotic are an important factor in 
determining appropriate dosage strategies to achieve therapeutic concentra-
tions for a sufficient duration to clear the infection, while avoiding the adverse 
side effects related to excessive drug levels [20]. Our model accounts for the 
gradual elimination of streptomycin that would be mediated by the kidneys 
during treatment. The fitness measurements along these decreasing drug con-
centrations may also affect the competition of resistant and sensitive bacteria. 
To illustrate the effect of decreasing concentration, Figure 4 considers two dif-
ferent pharmacodynamic scenarios. In the top panel of Figure 4A, we restrict 
the previously applied observation period to only seven days of daily strepto-
mycin treatment reaching a maximum of 40 ug/mL but then decays. Without 
the data on fitness measurements at intermediate drug concentrations, one 
would effectively simulate the effect of a single, continuous dosage (Figure 4B). 
Aside from the quantitative differences between the two situations, there are 
obvious qualitative disparities: the middle plot in Figure 4A displays the 
reemergence of the drug-sensitive +C strain as the antibiotic concentration 
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 drops during the last day of treatment. Furthermore, information on fitness 
across drug concentrations predicts the reemergence of sensitive bacteria in 
5/17 cases while the other scenario does not (bottom plots in Figure 4).  
 
Figure 4. Fitness across drug concentrations strongly affect the model 
The top plots in this figure show the pharmacodynamics of the streptomycin 
treatment regimes applied in the simulation. The middle plots depict the result-
ing population dynamics of a strain allowed to acquire compensatory allele #17. 
Finally, the bottom plots display the average composition of genotypes for each 
of the 17 sets of four genotypes at the end of the simulation 
A) Knowledge of the fitness landscapes of sensitive and resistant genotypes al-
lows for the consideration of intermediate drug concentrations during treatment 
on the population dynamics of sensitive and resistant bacteria. Sensitive bacteria 
are found to reemerge at low antibiotic levels in 5/17 conditions. 
B) Ignoring the effect of varying dosage on fitness produces qualitatively differ-
ent results – exemplified by the absence of any sensitive genotypes in every sce-
nario.   
 
Discussion 
The rugged fitness landscapes of a resistance mutation and its compensatory 
mutation partners could help reconcile conflicting clinical and laboratory 
studies.  
Our results suggest that mutations acquired to alleviate costly antibiotic 
resistance can both avert or aid reversion to a sensitive genotype contingent on 
both the specific allele and antibiotic concentration. Two primary features of the 
fitness landscapes we produced could aid in explaining the diverse array of 
findings across clinical and laboratory studies: First, increasing antibiotic con-
centration produces non-monotonic changes in the fitness of both sensitive and 
resistant bacteria. Second, a significant proportion of compensatory mutations 
27
 are neutral or beneficial in a resistant strain background even in the absence of 
the resistance mutation.  
Importantly, we find that the fitness of all four genotypes is strongly de-
pendent on antibiotic concentration. For all four genotypes, we find areas of the 
dose-response curve in which increasing drug concentration can either lower or 
raise fitness. This latter case is known as the Eagle effect: Eagle and Musselman 
first recognized that the dose-response curve for some antibiotics is not com-
pletely monotonic [21].  We observe this phenomenon in some of the sensitive 
genotypes (++ and some of the +Cs). However the degree of this effect and the 
antibiotic concentrations under which it is most evident vary across alleles. 
These results suggest that some specific sub-inhibitory drug concentrations may 
paradoxically favor sensitive over resistant bacteria.   
Furthermore, we also note the Eagle effect in the resistant genotypes. The 
rugged nature of the fitness landscapes for the R+ and RC strains demonstrates 
that the rpsL K42N resistance mutation does not render these genotypes insensi-
tive to the presence of streptomycin. It is conceivable that a different resistance 
mechanism such as an efflux pump would simply lower the intracellular drug 
concentration below the killing threshold while leaving the cell susceptible to 
other effects an antibiotic may induce. Our results indicate that even resistance 
mediated by a mutational target does not cause a strain to be completely im-
mune to antibiotics. Furthermore, the acquisition of different compensatory 
mutations by the resistant strain introduces additional epistatic effects on fit-
ness across drug concentration.  
Considering the effects of compensatory mutations on a resistant strain, 
the question of when and where a compensatory mutation exerts its influence 
has been addressed in numerous studies with a variety of results. These include 
broad effects in which a second-site mutation selected under particular experi-
mental conditions is only beneficial in that condition, or is also beneficial in an-
other environmental context, or even the extreme opposite in which a compen-
satory mutation leads to the dependence of the bacteria to the drug for growth 
[22–24]. Here, we find that the fitness increase imparted by C mutations select-
ed in the absence of drug continues even when drug is present – that is, RC 
strains have higher fitness than R+ across the majority of concentrations stud-
ied. Where and when the benefits of a compensatory mutation may manifest 
will affect the trajectory of the resistant genotypes who bear them as they com-
pete in the absence of antibiotics against wild type bacteria, or in the presence 
of drug treatment where other bacteria may contain resistance determinants 
that have little or no fitness cost.  
One of the most striking findings of this study is our description of se-
cond-site mutations that are advantageous independent of the resistance muta-
tion. The +C mutations that have beneficial effects without the resistance muta-
tion, by definition, are not compensatory. However, their absence during exper-
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 imental evolution of sensitive control lines and the significant proportion in 
which they are observed among mutations selected in resistant lines is puz-
zling. There are at least two possible explanations for why these beneficial mu-
tations are not found more frequently. 
First, our results consistently show that the fitness of both resistant and 
sensitive bacteria is dependent on antibiotic concentration, and their fitness can 
either increase or decrease in response to small increases of dosage. It is there-
fore likely that many other environmental cues will have strong effects on fit-
ness – the natural and even laboratory environment could then modulate or 
even determine whether the effects of these mutations will manifest. More spe-
cifically, compensatory mutations that may be acquired to alleviate costly re-
sistance in one environment may have a different effect in a resistant or sensi-
tive strain background in a new environment. This may help explain the dis-
crepancy between the frequencies of compensatory mutations observed in la-
boratory versus clinical studies. While laboratory experiments are most often 
conducted under similar if not identical conditions, pathogenic bacteria are ex-
posed to drastically different environments as they travel across the body’s 
compartments.  
Second, obtaining the resistance mutation could serve as a necessary step 
towards the acquisition of compensatory mutations that are either deleterious 
or beneficial in the absence of drug. Previous work has noted a comparable low 
fitness mutational step as a required intermediate to the acquisition of beneficial 
mutations. Fong and Palsson found that E. coli in whom metabolic genes have 
been knocked out evolved to have higher fitness than their ancestor [25]. The 
beneficial ribosomal mutations we characterized could imply that the evolution 
of costly antibiotic resistance may lead to the acquisition of a novel set of muta-
tions unavailable to the wild type.  
 
Compensatory mutations and varying antibiotic concentrations increase the 
number of evolutionary paths available to antibiotic resistant mutants 
As previous theoretical investigations on the influence of compensatory 
mutations in maintaining costly antibiotic resistance relied on data from only 
sensitive, resistant, and resistant and compensated strains, and only in a few 
antibiotic concentrations (namely in the absence or presence of antibiotics), we 
used our estimates of growth and death rates to re-evaluate this issue. Our 
model results illustrate how the combination of specific compensatory muta-
tions in different antibiotic-containing environments can produce a wide varie-
ty of effects on the population dynamics of sensitive and resistant bacteria.  
The result we find most substantial is that in the clinically relevant phar-
macodynamic condition, all the 17 scenarios contain both resistant and sensitive 
bacteria at the end of the observation period. This diversity is facilitated by de-
pendence of the fitness of all genotypes on drug concentration, suggesting a 
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 previously unrecognized role of antibiotic concentration in aiding the 
reemergence of sensitive bacteria.  
As a future direction of this work, we are adapting our model to allow the 
acquisition of all possible C mutations. Removing the restriction will allow for 
the competition between different +Cs and RCs and not just between the sensi-
tive and resistant versions of a specific C allele.  
Taken together, the combination of our empirical and theoretical investi-
gations on compensatory mutations highlight the importance of both specific 
alleles and environmental context. Our work serves as the most comprehensive 
study to date of the effects of mutations acquired in the absence of antibiotics to 
alleviate the cost of a resistance mutation also in the absence of antibiotics. The 
drug-dependent fitness landscapes we explored suggest that antibiotic concen-
tration could play an important role in maintaining or disfavoring costly re-
sistance. Our investigation of the relationship between genotype and drug con-
centration serves as an important initial step in predicting and possibly ma-
nipulating the evolutionary trajectory of antibiotic resistant bacteria.   
 
Methods 
Strains and Media 
The variants of the Salmonella enterica serovar Typhimurium LT2 strain used 
in this study were originally created and described in Maisnier-Patin et al, Mol 
Micro 2002 [9]. In brief, the authors asked where and what sort of mutations 
could compensate for a single costly antibiotic resistant. They replicate and se-
rially passage a streptomycin-resistant strain bearing a K42N mutation in rpsL 
in drug-free broth until they detect an increase in fitness. Target genes from the 
resulting replicate cultures are then sequenced leading to the identification of 
compensatory mutations.  These single nucleotide substitutions were then sepa-
rated and transduced into the ancestral drug resistant background, as well as to 
the ancestral background lacking the resistance mutation. Our study population 
consists of the ancestral antibiotic sensitive and resistant strains, 17 strains bear-
ing the resistance mutation and a single identified compensatory mutation each, 
and 17 strains containing only the compensatory mutations (Supplementary 
Table 1). All experiments are carried out in LB media at 37°C.   
 
Measurements of Fitness: Growth curves and Kill curves 
Fitness as exponential growth rate was assessed for all strains in different 
streptomycin-containing environments. This was determined as changes in op-
tical density over time at 600 nm (OD600nm).  
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 Aside from growth rates measured in sub-inhibitory concentrations of 
streptomycin, the death rates of all drug sensitive strains were measured by 
taking cells in exponential phase and adding them to LB broth containing the 
MIC and 5X the MIC of streptomycin (20ug/mL and 100ug/mL). The resulting 
culture was then sampled at regular intervals via plating to determine the 
number of colony-forming units. In addition, some genotypes exhibit increased 
sensitivity to the drug and the death rates for these strains were also obtained at 
every streptomycin concentration below 20 ug/mL.  
The growth or death rates of all strains were measured in the following 
concentrations of streptomycin in ug/mL: 0, 0.5, 2.5, 5, 10, 15, 20, 100. Addition-
ally, the growth rates of all resistant strains were measured in the following 
concentrations: 40, 60, 80, 100, 1000, 10000. 
 
Model Description 
In order to gain a better understanding of the evolutionary dynamics of 
compensatory mutations in the presence of drugs at varying concentrations, we 
constructed a mathematical model of a bacterial population evolving under mu-
tation and natural selection. In this model, we consider the four genotypes ++, 
R+, C+ and RC, where C can be any of our experimentally studied compensato-
ry mutations. Let 𝑁! be the number of bacteria of genotype i 
(𝑖 ∈ {++, R+, +C, RC}). The in vitro net growth rate of genotype i at a given drug 
concentration A is given by our fitted fitness function for that genotype, 𝑤!(𝐴). 
We assume that this net growth is a composite of (1) baseline growth that is de-
pendent on genotype, (2) natural death at a rate d that is independent of geno-
type, and (3) additional death imposed by the antibiotics, depending on both 
genotype and antibiotic concentration. Moreover, we assume that growth is 
density dependent with carrying capacity K and that under in vivo conditions, 
growth may reduced by a factor r. Mutations occur at rates 𝜇! and 𝜇!  at the re-
sistance and compensation locus, respectively, and we assume that forward and 
backward mutations occur at the same rate. 
With these assumptions, we arrive at the following system of ordinary dif-
ferential equations: 𝑑𝑁!!𝑑𝑡 = 𝑁!! 𝑟𝑤!!!"# + 𝑑 1 − 𝑁𝐾 − 𝑁!! 𝑤!!!"# − 𝑤!! 𝐴 + 𝑑  − 𝜇! + 𝜇! 𝑁!! + 𝜇!𝑁!! + 𝜇!𝑁!!  𝑑𝑁!!𝑑𝑡 = 𝑁!! 𝑟𝑤!!!"# + 𝑑 1 − 𝑁𝐾 − 𝑁!! 𝑤!!!"# − 𝑤!! 𝐴 + 𝑑  − 𝜇! + 𝜇! 𝑁!! + 𝜇!𝑁!! + 𝜇!𝑁!"  
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 𝑑𝑁!!𝑑𝑡 = 𝑁!! 𝑟𝑤!!!"# + 𝑑 1 − 𝑁𝐾 − 𝑁!! 𝑤!!!"# − 𝑤!! 𝐴 + 𝑑  − 𝜇! + 𝜇! 𝑁!! + 𝜇!𝑁!" + 𝜇!𝑁!! 𝑑𝑁!"𝑑𝑡 = 𝑁!" 𝑟𝑤!"!"# + 𝑑 1 − 𝑁𝐾 − 𝑁!" 𝑤!"!"# − 𝑤!" 𝐴 + 𝑑  − 𝜇! + 𝜇! 𝑁!" + 𝜇!𝑁!! + 𝜇!𝑁!! 
 
Here, 𝑤!!"# = 𝑤! 0  is the estimated net growth rate of genotype i in the 
absence of drugs, and 𝑁 = 𝑁!! + 𝑁!! + 𝑁!! + 𝑁!"  is the total population size. 
We solved these differential equations numerically using the package deSolve 
implemented in R (The R Foundation for Statistical Computing; http://www.R-
project.org). 
For the simulation of pharmacokinetics, we assume that the maximal con-
centration is reached instantaneously and that the drug concentration decays 
with a first order kinetics e-kt with k = 0.1. 
 
Table 1. Parameters used in the model 
Parameter Value Reference 
Carrying capacity (K) 109  
Mutation rate at re-
sistance locus  
10-9 [26] 
Mutation rate at com-
pensation locus 
10-9 [26] 
Death rate 1/24 [/h] [27] 
Growth rate 0.092 [/h] [27] 
 
Author contributions 
All authors conceived and designed the experiments. PSO performed all 
the experiments. PSO, JE, and PAzW analyzed the results. JE and PAzW formu-
lated the model. PSO wrote the paper. All authors discussed the results and 
implications and commented on the manuscript. 
 
32
 References 
1.  Fridkin S, Hageman J, Morrison M, Thomson Sanza L, Como-Sabetti 
K, et al. (2005) Methicillin-resistant Staphylococcus aureus disease in 
three communities. N Engl J Med 352: 1436–1444. 
2.   Klein E, Smith DL, Laxminarayan R (2009) Community-associated 
methicillin-resistant Staphylococcus aureus in outpatients, United 
States, 1999-2006. Emerg Infect Dis 15: 1925–1930. 
doi:10.3201/eid1512.081341. 
3.  Chambers HF, DeLeo FR (2009) Waves of resistance: Staphylococcus 
aureus in the antibiotic era. Nat Rev Micro 7: 629–641. 
4. Gustafsson I, Cars O, Andersson DI (2003) Fitness of antibiotic re-
sistant Staphylococcus epidermidis assessed by competition on the 
skin of human volunteers. J Antimicrob Chemother: 258–263. 
doi:10.1093/jac/dkg331. 
5.  Andersson DI, Levin BR (1999) The biological cost of antibiotic re-
sistance. Curr Opin Microbiol 2: 489–493. 
6. Schrag SJ, Perrot V, Levin BR (1997) Adaptation to the fitness costs of 
antibiotic resistance in Escherichia coli. Proc Roy Soc B 264: 1287–
1291. doi:10.1098/rspb.1997.0178. 
7. Reynolds MG (2000) Compensatory Evolution in Rifampin-
Resistant. Genetics 156:1471-81. 
8.  Maisnier-Patin S, Andersson DI (2004) Adaptation to the deleterious 
effects of antimicrobial drug resistance mutations by compensatory 
evolution. Res Microbiol 155: 360–369. 
doi:10.1016/j.resmic.2004.01.019. 
9.  Maisnier-Patin S, Berg OG, Liljas L, Andersson DI (2002) Compensa-
tory adaptation to the deleterious effect of antibiotic resistance in. 
Mol Microbiol: 355–366. 
10.  Cortes PR, Cian MB, Albarracı AG (2011) Compensatory Evolution 
of pbp Mutations Restores the Fitness Cost Imposed by b-Lactam 
Resistance in Streptococcus pneumoniae. PLoS Pathog 7: e1002000. 
doi:10.1371/journal.ppat.1002000. 
33
 11.  Nagaev I, Björkman J, Andersson DI, Hughes D (2001) Biological 
cost and compensatory evolution in fusidic acid-resistant Staphylo-
coccus aureus. Mol Microbiol 40: 433–439. 
12.  Böttger E, Springer B, Pletschette M, Sander P (1998) Fitness of anti-
biotic-resistant microorganisms and compensatory mutations. Na-
ture Medicine 4: 11–12. 
13.  Paulander W, Maisnier-Patin S, Andersson DI (2007) Multiple mech-
anisms to ameliorate the fitness burden of mupirocin resistance in 
Salmonella typhimurium. Mol Microbiol 64: 1038–1048. 
doi:10.1111/j.1365-2958.2007.05713.x. 
14.  Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, et 
al. (2004) Reversion to susceptibility in a linezolid-resistant clinical 
isolate of Staphylococcus aureus. J Antimicrob Chemother 54: 818–
820. 
15.  Luo N, Pereira S, Sahin O, Lin J, Huang S, et al. (2005) Enhanced in 
vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the 
absence of antibiotic selection pressure. Proc Natl Acad Sci  USA 102: 
541–546. doi:10.1073/pnas.0408966102. 
16.  Huang T-D, Almpanis C, Denis O, Nonhoff C, Delaere B, et al. (2007) 
Reversion of resistance in relapsing infection caused by a glycopep-
tide-intermediate methicillin-resistant Staphylococcus aureus isolate. 
Eur J Clin Microbiol Infect Dis 26: 419–422. doi:10.1007/s10096-007-
0297-1. 
17.  Schulz zur Wiesch P, Engelstädter J, Bonhoeffer S (2010) Compensa-
tion of fitness costs and reversibility of antibiotic resistance muta-
tions. Antimicrob Agents Chemother 54: 2085–2095. 
doi:10.1128/AAC.01460-09. 
18.  Tanaka M, Valckenborgh F (2011) Escaping an Evolutionary Lobster 
Trap: Drug Resistance and Compensatory Mutation in a Fluctuating 
Environment. Evolution 65: 1376–1387. doi:10.1111/j.1558-
5646.2011.01223.x. 
19.  Bergstrom C, Feldgarden M (2008) The ecology and evolution of an-
tibiotic-resistant bacteria. In: Stearns S, Koella J, editors. Evolution in 
health and disease. New York: Oxford Univ Press. pp. 125–137. 
34
 20.  Zhu M, D P, Burman WJ, Jaresko GS, D P, et al. (2001) Population 
Pharmacokinetics of Intravenous and Intramuscular Streptomycin in 
Patients with Tuberculosis. Pharmacother 21(9):1037-45 . 
21.  Eagle H, Musselman A (1948) The rate of bactericidal action of peni-
cillin in vitro as a function of its concentration, and its paradoxically 
reduced activity at high concentrations against certain organisms. J 
Exp Med 88(1): 99-131. 
22.  Baptista M, Depardieu F, Reynolds P, Courvalin P, Arthur M (1997) 
Mutations leading to increased levels of resistance to glycopeptide 
antibiotics in VanB-type enterococci. Mol Microbiol 25: 93–105. 
23.  Périchon B, Courvalin P (2009) VanA-type vancomycin-resistant 
Staphylococcus aureus. Antimicrob Agents Chemother 53: 4580–
4587. doi:10.1128/AAC.00346-09. 
24.  Moubareck C, Meziane-Cherif D, Courvalin P, Périchon B (2009) 
VanA-type Staphylococcus aureus strain VRSA-7 is partially de-
pendent on vancomycin for growth. Antimicrob Agents Chemother 
53: 3657–3663. doi:10.1128/AAC.00338-09. 
25.  Fong SS, Palsson BØ (2004) Metabolic gene-deletion strains of Esche-
richia coli evolve to computationally predicted growth phenotypes. 
Nature Genetics 36: 1056–1058. doi:10.1038/ng1432. 
26.  Drake JW (1991) A constant rate of spontaneous mutation in DNA-
based microbes. Proc Natl Acad Sci USA 88: 7160–7164. 
27.  Grant AJ, Restif O, Mckinley TJ, Sheppard M, Maskell DJ, et al. 
(2008) Modelling within-Host Spatiotemporal Dynamics of Invasive 
Bacterial Disease. PLoS Biol 6: e74. doi:10.1371/journal.pbio.0060074. 
doi:10.1371/journal.pbio.0060074.  
 
  
35
  
Supplementary Figure 1. Fitness landscapes of all strains used in the study.  
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 Supplementary Table 1. List of strains and genotypes used in the study 
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 Abstract 
Aside from death, antibiotics induce many different morphologic, physio-
logic, and genetic changes in drug sensitive bacteria. It is currently not clear, 
however, whether antibiotics can similarly affect antibiotic resistant bacteria, or 
what kind of changes this may include. In studying the costs of resistance to 
one drug in antibiotic stress, we found an unexpected effect of streptomycin on 
the fitness of future generations of streptomycin-resistant (SmpR) bacteria in a 
second drug. Although sensitive and SmpR E. coli first grown in plain media for 
24 hours both displayed slightly decreased growth rates when transferred to 
fresh media supplemented with sub-inhibitory chloramphenicol, SmpR bacteria 
first grown in streptomycin and then exposed to low chloramphenicol levels 
exhibited growth rates significantly higher than wild type bacteria in the ab-
sence of any drug. This priming effect of streptomycin on SmpR strains was 
found to be transient, specific for chloramphenicol, and required a concentra-
tion of streptomycin that is inhibitory to sensitive cells. Whole genome sequenc-
ing needs to be performed to determine the mutations underlying this mecha-
nism. In this chapter, we describe the experiments performed to define this 
novel phenomenon, and discuss the implications this may have on our under-
standing of antibiotic resistance.  
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 Introduction 
The costs associated with a resistance determinant are among the most 
important factors in determining both the speed and extent of the emergence of 
resistance [1–4]. Bacteria have at their disposal a variety of mechanisms by 
which they reduce or even remove these costs. These include the evolution of a 
second-site compensatory mutation (see Chapter 2), or by evolving regulatory 
mechanisms that control the expression of resistance genes [5].  
An important consideration in measuring these costs is that environmen-
tal conditions have been found to have significant influence. As an example, 
some specific resistance mutations that have been shown to be cost-free in in 
vitro experiments have high costs when grown in laboratory mice, and the re-
verse has also been reported with costs revealed in laboratory media and absent 
in mice [6,7].  
Much more generally, Kishony and Leibler have shown that a variety of 
environmental stressors can reduce the average cost of random deleterious mu-
tations [8]. Among these cost-alleviating stressors they identified are sub-
inhibitory concentrations of two antibiotics of differing mechanisms of action, 
chloramphenicol and trimethoprim.  
In this study, we initially sought to determine whether these same stress-
ors – low concentrations of antibiotics - were able to reduce the cost of defined 
deleterious mutations, specifically antibiotic resistance mutations. Recent stud-
ies suggest that antibiotics used in human or veterinary medicine may be leak-
ing into the environment and influencing the rise of resistant infections [9]. De-
termining whether sub-inhibitory concentrations of various antibiotics alleviate 
the burden of costly resistance could aid in defining the link between antibiotic 
pollution and community-acquired resistant infections.  
Unforeseen results lead to a reorientation of the project to instead charac-
terize a novel phenomenon. The original experimental design involved obtain-
ing resistant bacteria. This was achieved by plating an overnight culture of E. 
coli on solid LB media supplemented with streptomycin to select for streptomy-
cin resistant (SmpR) mutants. The growth rates of the resulting strains would 
be measured in the presence of antibiotic stress. In contrast to previous work on 
random deleterious mutations, we did not find that exposure to sub-inhibitory 
concentrations of a second antibiotic alleviated the cost of resistance. Instead, 
we found that the growth conditions 24 hours prior to the experimental treat-
ment had a strong effect on fitness. In this chapter, I report on the experiments 
performed to describe this novel, environment-specific effect and discuss the 
possible implications this may have on the current concept of antibiotic re-
sistance.  
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Results 
These results are based on a set of 20 SmpR E. coli strains that were gener-
ated via plating on LB agar supplemented with 100 ug/mL of streptomycin 
over 48 hours. The general design of the experiment involves streaking a frozen 
culture of the previously isolated SmpR strains – or wild-type strains as con-
trols - onto a plain LB plate followed by incubation overnight at 37°C. Eight in-
dividual colonies of each strain are used to each inoculate a single well in a 96-
well plate containing media with or without streptomycin (pre-culture per-
formed on day 0). After overnight incubation, the pre-culture is diluted 10,000x 
into a second 96-well plate containing fresh media with or without a second an-
tibiotic (experimental condition performed on day 1).  
Resistant strains pre-cultured in plain media and then exposed to sub-
inhibitory concentrations of chloramphenicol (0.2 ug/mL) had slightly lower 
fitness than wild type. However, pre-culture in streptomycin primed the re-
sistant strains to display significantly increased growth in chloramphenicol 
(Fig. 1). Strikingly, primed resistant strains in chloramphenicol have significant-
ly higher growth than the ancestral strain in plain media.  
It is important to note that repeated attempts at isolating SmpR strains 
that display this effect by plating new cultures of the ancestral strain on strep-
tomycin have been unsuccessful. The growth rate measurements in chloram-
phenicol for the available strains, however, have been replicated many times 
and results have been consistent. 
 
 
 
 
41
  
Figure 1. High concentrations of streptomycin increase transgenerational 
fitness in sub-inhibitory chloramphenicol.  
Each boxplot depicts the fitness of 20 SmpR strains in four experimental treat-
ments relative to the ancestral wild type measured in plain LB. The conditions 
from L to R are as follows: (1) pre-cultured in LB and then measured in LB, (2) 
pre-cultured in LB and then measured in chloramphenicol, (3) pre-cultured in 
streptomycin and then measured in LB, and (4) pre-cultured in streptomycin and 
then measured in chloramphenicol. While cells in condition (2) had significantly 
lower fitness than (1), unpaired, two-tailed t-test assuming unequal variance, p = 
0.0003, changing the pre-culture treatment to condition (4) resulted in significant-
ly higher fitness, p<10-12. The edges of the box mark the 25th and 75th percentile, 
the horizontal line marks the median, the whiskers denote the maximum and 
minimum of all the data.  
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 Priming is antibiotic-specific 
The experimental treatment was repeated with the substitution of a sub-
inhibitory concentration of the folic acid synthesis inhibitor trimethoprim (0.2 
ug/mL) instead of chloramphenicol (Figure 2). The fitness of the resistant 
strains pre-cultured in either plain broth or with streptomycin was both found 
to decrease slightly and were not significantly different from each other. 
Growth rate measurements performed in two other concentrations of trime-
thoprim, 0.02 and 0.1 ug/mL, did not produce any discernible effect on fitness 
of the resistant strains (results not shown).  
 
 
Figure 2. Transgenerational fitness benefit is not induced by sub-inhibitory 
concentrations of trimethoprim.  
The relative fitness of SmpR strains is not significantly different from the wild 
type during exposure to the folate inhibitor trimethoprim. (unpaired, two-tailed 
t-test assuming unequal variance, p=0.77) 
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 Increased fitness is partly due to an interaction of chloramphenicol and di-
lute concentrations of streptomycin  
Since there was no washing step in between the pre-culture and experi-
mental conditions, it is possible that the high fitness observed by primed strains 
in a second antibiotic is due to a direct interaction between diluted streptomy-
cin and chloramphenicol. To test this, un-primed strains were grown in sub-
inhibitory chloramphenicol and a range of low streptomycin concentrations. To 
rule out whether the incubation step had an effect on streptomycin, LB with 100 
ug/mL streptomycin was shaken at 37°C without cells and then diluted 10,000x 
before being applied to resistant cultures with chloramphenicol (Figure 3). The 
combination of a low streptomycin concentration and chloramphenicol induced 
a fitness increase significantly higher than strains pre-cultured in LB and grown 
in LB (unpaired, two-tailed t-test assuming unequal variance, p=0.02). Howev-
er, the magnitude of the increase of growth rate of strains in the combination 
treatment is significantly lower than the magnitude of the increase observed in 
primed strains (unpaired, two-tailed t-test assuming unequal variance, 
p=0.0002). This indicates that the combination of low streptomycin and low 
chloramphenicol is at least partially responsible for the fitness increase we ob-
serve, but does not explain its full magnitude, suggesting that priming has a 
significant effect on its own.  
 
Figure 3. Transgenerational fitness benefit is partially the product of sub-
inhibitory chloramphenicol and diluted streptomycin.  
The fitness difference between the population of resistant strains pre-cultured in 
LB and then grown either in LB or the combination of 0.2 ug/mL chlorampheni-
col and 0.01 ug/mL streptomycin is significant (unpaired, two-tailed t-test as-
suming unequal variance, p = 0.02). The significant difference in the magnitude 
of the increase in growth rate between strains exposed to the combination condi-
tion and strains pre-cultured in streptomycin before growth in chloramphenicol 
suggests that the combination condition is only partially responsible (unpaired, 
two-tailed t-test assuming unequal variance, p=0.0002). 
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 Priming effect is streptomycin-concentration dependent 
The standard experimental condition to induce the increased growth effect 
in chloramphenicol was to prime the SmpR strains in the concentration of strep-
tomycin used to initially select for resistance (100 ug/mL). Lowering the strep-
tomycin concentration used in priming to 10 ug/mL or 1 ug/mL resulted in the 
absence of increased growth in chloramphenicol (Figure 4).  
 
 
Figure 4. Priming with sub-inhibitory concentrations of streptomycin does not 
produce the transgenerational fitness benefit during exposure to sub-
inhibitory chloramphenicol.  
Cells pre-cultured in LB and grown in Cm 0.2 exhibited lower growth rates than 
cells pre-cultured in LB and grown in LB (unpaired, two-tailed t-test assuming 
unequal variance, p = 0.0003). Considering the effect of sub-inhibitory streptomy-
cin in the pre-culture condition, exposure to 1 ug/mL of streptomycin resulted in 
a significant decrease in growth rate in Cm 0.2 compared to LB (unpaired, two-
tailed t-test assuming unequal variance, p = 0.03). However pre-culture in 10 
ug/mL of streptomycin resulted in a significant increase in growth in Cm 0.2 
compared to cells pre-cultured in LB and grown in LB (unpaired, two-tailed t-test 
assuming unequal variance, p = 0.05 respectively).  
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 Effect is transient and not stably inherited 
In order to determine whether the effect in chloramphenicol induced by 
streptomycin was permanent or transient, the experimental design was modi-
fied to include a passage in fresh LB broth for 24 hours at 37°C between the pre-
culture condition and the experimental condition. This resulted in strains from 
either pre-culture condition displaying growth rates that were not significantly 
different (Figure 5).  
 
Figure 5. The addition of a serial passage step resulted in the negation of the 
transgenerational fitness benefit in sub-inhibitory chloramphenicol. 
Pre-culturing in Smp, followed by passaging in LB, and then growth in Cm did 
not vary significantly from pre-culturing in Smp, passaging in LB, and growth in 
LB (unpaired, two-tailed t-test assuming unequal variance, p = 0.85) 
 
Priming with streptomycin does not result in resistance to chloramphenicol 
Each of the 20 SmpR strains were grown in LB with or without streptomy-
cin at 37°C overnight. The resulting culture was used to perform a standard 
minimum inhibitory concentration (MIC) estimate for chloramphenicol. All cul-
tures, regardless of pre-culture conditions, had an MIC for chloramphenicol of 5 
ug/mL.  
 
Streptomycin resistance mutations 
Sequencing was performed on the rpsL gene of all recovered SmpR clones. 
Results reveal 4 different well-characterized streptomycin resistance mutations. 
Of the 20 different clones, eight bear the K43N mutation, six have K88R, four 
contain K42T, and two have K87R. A one-way analysis of variance yielded no 
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 significant differences between the transgenerational benefit of the four differ-
ent mutations, F(3,13) = 0.667, p = 0.58.  
 
Discussion 
Dependent on concentration, we are aware of a wide variety of responses 
induced by antibiotics – in sensitive bacteria. In contrast, little consideration is 
paid to how antibiotics at any concentration affect resistant bacteria. Here, I add 
to the understanding of how antibiotics influence resistant bacteria by describ-
ing a novel phenomenon in which the succeeding generations of resistant bacte-
ria may experience additional benefits. Specifically, the experiments performed 
in this chapter draw attention to three principal findings: 
 
First, that the acquisition of streptomycin resistance may lead to effects 
unrelated to survival in the presence of a drug. It must first be noted that alt-
hough bacteria that have acquired resistance mutations will obviously thrive in 
high levels of a particular drug, they may not be completely insensitive to the 
presence of that drug. In Chapter 2, I show how the dose-response curves for 
many different resistant genotypes in a wide range of antibiotic concentrations 
display non-monotonic changes in growth rate as antibiotic concentration in-
creases. Conceivably, this could occur via the formation of weak, highly re-
versible bonds between streptomycin and its binding site on the bacterial ribo-
some. This could result in perturbations to normal cell physiology that mani-
fests as fluctuations in growth rate. The results I present in this chapter suggest 
that the acquisition of streptomycin resistance mutations may produce addi-
tional effects besides increased survival in streptomycin. Three examples of 
such unforeseen effects are discussed below; these include increased ribosomal 
accuracy, differences in virulence, and increased growth in the presence of a se-
cond antibiotic. 
Mutations that grant streptomycin resistance can be divided into two clas-
ses: Error-restrictive mutations on rpsL increase the accuracy of inspection of 
codon-anticodon pairings on the ribosomal A site, resulting in decreased rates 
of peptide elongation and decreased growth rates [10]. Non-restrictive muta-
tions have also been described and these have similar accuracy and growth rate 
as wild type strains. Interestingly, these classes are allele-specific – for example, 
K42T and K42N are both restrictive while K42R is not [11].  
Furthermore, the acquisition of different types of resistance mutations has 
been found to result in disparities in other traits such as virulence. The food-
borne pathogen, enterohemorrhagic E. coli O157:H7 containing restrictive strep-
tomycin resistance mutations were found to have decreased expression and se-
cretion of EspA and EspB, two proteins required for attaching and effacing to 
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 the intestinal epithelium. In contrast, nonrestrictive mutants displayed little or 
insignificant changes in secretion levels [12].  
Interestingly, a phenomenon related to the fitness benefit described in this 
chapter has been recently reported. Pelchovich and colleagues asked whether 
the structural alterations that accompany streptomycin resistance mutations 
would affect sensitivity to other antibiotics that target the ribosome [13]. Alt-
hough all their pre-culture conditions involved growth in LB broth, they ob-
served a range of fitness effects during exposure to unrelated antibiotics. De-
creased growth rates occurred in SmpR strains grown in sub-lethal chloram-
phenicol and tetracycline; in contrast they also found that these mutants had 
higher growth rates than wild type bacteria in a sub-inhibitory concentration of 
gentamicin. These results provide additional support for a strain bearing a re-
sistance mutation to experience higher fitness in the presence of an antibiotic to 
which it is sensitive. This may suggest a weak form of cross-resistance. The re-
sults detailed in this chapter, however, indicate that investigations on the effects 
of antibiotics on the fitness of resistant bacteria should also consider the pre-
culture condition.  
 
Second, the phenomenon I describe is broadly consistent with other cryp-
tic or unrecognized bacterial mechanisms in terms of reliance on concentration. 
Since antibiotics specifically target essential components of bacterial physiolo-
gy, it is conceivable that the degree of an effect or even different kinds of effects 
can accompany increasing drug concentrations. For example, sub-inhibitory 
concentrations of the fluoroquinolone ciprofloxacin has been found to potenti-
ate the production of cytolethal distending toxin, an important component in 
the pathogenesis of C. jejuni  [14]. At higher concentrations, fluoroquinolones 
induce the SOS response and this promotes many responses such as the for-
mation of persisters [15]. Awareness of these effects could aid in devising dos-
age strategies that avoid the induction of concentration-dependent responses, 
or capitalize on them in a way that maximizes treatment efficacy.  
 
The last important consideration raised by these experiments is the trans-
generational but transient effects antibiotics may produce in resistant strains. In 
a related fashion, transient responses of bacteria to antibiotics is explored in 
Chapter 4 (See Figure 3 for filamentation during exposure to some drugs) and 
discussed further in Chapter 5. Conceptually, this transgenerational effect could 
be linked to the well-studied general stress response of bacteria. The SOS re-
sponse is triggered by a wide range of environmental cues, including many an-
tibiotics, and could aid the future success of bacterial progeny. These could be 
transient effects such as persistence, or permanent changes including the evolu-
tion of resistance in daughter cells via error-prone DNA replication or recombi-
nation of divergent sequences, or the acquisition of mobile genetic elements 
48
 that often harbor resistance genes [15,17,18]. The effect we observe in SmpR E. 
coli appears heritable to a certain extent and then ceases, and is contingent on an 
unexpected environmental context – the presence of inhibitory concentrations 
of streptomycin.   
 
Future direction 
Whole genome sequencing is currently being performed in order to de-
termine whether this effect has a detectable genetic basis. Aside from this, a 
number of experiments are planned to better understand this phenomenon: 
First, observations at the single cell level using microfluidic devices are to 
be performed on these mutants to determine whether all or only a few individ-
uals are responsible for the increased growth rates observed after pre-culture in 
streptomycin. We envision at least two possible scenarios underlying the in-
creased growth of pre-treated SmpR strains in chloramphenicol that we hope to 
clarify using these experiments.  
It is possible that the pre-culture condition involving a sufficiently high 
streptomycin concentration may enrich the population by selecting for certain 
genotypes or phenotypes. This sub-population of cells may exhibit increased 
growth while the rest does not. Conversely, the pre-culture condition may also 
induce a physiological change in all cells.  
Moreover, determining whether there are differences in growth rates 
among individual cells may help identify an interaction between cell types that 
could explain increased growth of these SmpR strains in chloramphenicol. A 
similar phenomenon has been reported by Lee and colleagues as they examined 
the population dynamics of bacteria during drug exposure [16]. They began by 
following a continuous culture of Escherichia coli exposed to increasing drug 
concentrations and found that most individuals were more sensitive than the 
population as a whole. They isolated a few highly resistant mutants and deter-
mined how these cells improve the survival of the whole population by produc-
ing indole in response to the presence of antibiotics. Transcriptional profiling 
revealed how this signaling molecule induces drug efflux pumps and oxidative-
stress protective mechanisms in sensitive members of the population. These ob-
servations demonstrate how a few resistant individuals can influence a suscep-
tible population to survive antibiotic treatment without explicitly evolving re-
sistance.  
Second, these experiments are to be repeated using additional antibiotics 
to determine the extent of this effect across different environments. The chlo-
ramphenicol-specific nature of the inducible fitness increases we measure high-
lights the importance of placing antibiotic resistance in an assortment of envi-
ronmental contexts. Various environments as well as various stressors, includ-
ing antibiotics, have already been revealed to produce a wide selection of re-
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 sponses from sensitive bacteria. These include transitioning from normal, bacil-
lary growth to filamentous growth, or even stopping growth entirely (see Chap-
ter 4 and 5 for a more detailed discussion of filamentation and bacteriostasis). It 
is thought that revealing this “hidden” variation of responses in stressful envi-
ronments results from perturbations on normal homeostasis; this in turn may 
itself be adaptive as an increase in variation may lead to the selection of novel 
beneficial adaptations [19]. Conversely, “hidden” variation may also include 
adverse affects. This is evident when placing the effects of fusA mutations in 
different environmental contexts. These mutations grant fusidic acid resistance 
to S. enterica by altering expression of the transcriptional regulator guanosive 
tetraphosphate (ppGpp). This results in pleiotropic effects on gene expression 
that lead to environment-dependent fitness differences, including hypersensi-
tivity to unrelated antibiotics [20].  Our results suggest that uncovering “hid-
den” variation in fitness in new environments can be an inducible event. We 
show that increased growth in stressful environments can be observed in SmpR 
bacteria if they are first exposed to streptomycin.  
Finally, we plan to further investigate the combined effect of low strepto-
mycin and low chloramphenicol in increasing growth rate (detailed in Figure 
3). The next chapter in this thesis considers every pairwise combination of 21 
different antibiotics and the effect these pairs may have on the growth and 
death of wild type E. coli. The results reported in this chapter suggest that prob-
ing how a wide range of different concentration combinations may affect bacte-
rial physiology could lead to the identification of novel phenomena.  
Currently, we can only speculate as to what molecular mechanism may 
underlie this novel phenomenon. Regardless of the mechanism that leads to this 
increase in growth rate, the significant effect of streptomycin on SmpR bacteria 
draws attention to how our understanding of antibiotic resistance may be in-
complete. These results highlight the importance of drug concentration and en-
vironmental context in studying resistance. 
 
 
Methods 
Strains and Media 
All strains were derived from an Escherichia coli MG1655 lacZ::gfp strain 
obtained from the lab of Marjan van der Woude [21]. 20 streptomycin resistant 
variants were selected via plating of an overnight culture onto LB plates con-
taining 100 ug/mL streptomycin. Sequencing of the rpsL gene of these strains 
revealed only previously reported streptomycin resistance mutations. All ex-
periments were performed in LB broth at 37°C.  
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 Growth rate measurements 
Fitness as exponential growth rate was determined as changes in optical 
density over time at 600 nm (OD600nm). In brief, the ancestral sensitive strain was 
grown overnight at 37°C in LB before being diluted 10000x into fresh media 
with or without drugs. All 20 streptomycin resistant strains were similarly pre-
cultured in plain broth, or in broth supplemented with streptomycin, before be-
ing subjected to the same growth conditions as the ancestral strain. The relative 
fitness of each strain was calculated as a ratio of the growth rate of the ancestral 
wild type strain pre-cultured in LB and measured in LB divided by the growth 
rate of the mutant strain in the appropriate pre-culture and experimental condi-
tion. 
 
Statistical analysis 
All statistical tests were performed in JMP. 
 
 
 
Author contributions  
All authors conceived and designed the experiments. PSO performed the 
experiments and wrote the paper. All authors discussed the results and implica-
tions and commented on the manuscript.  
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 Abstract 
Combination therapy is rarely used to counter resistance evolution in bac-
terial infections. An expansion of combination therapy requires knowledge of 
how drugs at inhibitory concentrations interact. Such knowledge is essential for 
exploiting the benefits of combination therapy. Previously it has been suggested 
that if bactericidal drugs are most potent on actively dividing cells, then the in-
hibition of growth induced by a bacteriostatic drug should result in a reduction 
of drug efficacy. Our goal here was to investigate this hypothesis systematical-
ly. We performed an initial screen of pairwise combinations across 21 different 
antibiotics at sub-inhibitory concentrations, and found that combining a bacte-
riostatic with a bactericidal drug has a strong tendency to result in antago-
nism.  Using a subset of these pairs, we extended the analysis to high drug con-
centrations by constructing time-kill curves, and verified the antagonistic inter-
actions between bacteriostatic and bactericidal drugs at clinically relevant drug 
concentrations. As our hypothesis relies on a phenotypic effect produced by dif-
ferent drug classes, we recreated these experiments in a microfluidic device and 
performed time-lapse analyses to directly observe and quantify growth and di-
vision of individual cells under controlled antibiotic concentrations. While our 
single-cell observations supported the antagonism between bacteriostatic and 
bactericidal drugs, they revealed an unexpected variety of cellular responses to 
antagonistic drug combinations, suggesting that multiple mechanisms underlie 
this interaction. These results provide a necessary step towards exploiting drug 
interactions for the treatment of bacterial infections and the prevention of re-
sistance evolution.  
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 Introduction 
The problem of antibiotic resistance requires a solution that relies on more 
than just the continuous development of new drugs. Pathogens have been unre-
lentingly cunning in evolving mechanisms by which to survive in the face of 
every drug put on the market. Our response must be careful and far-sighted. 
Combination therapy, the concurrent application of two or more antibiotics, 
provides an appealing regimen that demands closer assessment as a tool to 
combat this problem. In the treatment of important infectious diseases such as 
HIV, tuberculosis, and malaria, combination therapy has become the gold 
standard precisely to delay the evolution of drug resistance [1–4]. In contrast, 
among common acute bacterial infections, combinations of drugs are only pre-
scribed in a very limited number of cases and for a different rationale. For those 
specific instances, two drugs are prescribed for their synergistic effect, that is, 
for the fact that their combined effect exceeds the sum of their individual ef-
fects. Drug synergy had been demonstrated to affect clearance of the infection 
more efficiently and at lower drug concentrations [5]. Examples of such cases 
include fusidic acid and rifampin for the treatment of methicillin-resistant S. au-
reus or trimethoprim and sulfamethoxazole for otitis media [6,7]. Furthermore, 
recent theoretical work indicates that synergistic drugs can prevent treatment 
failure even when bacteria resistant to one of the drugs is present at the begin-
ning of therapy [8].   
The principle advocating synergy between antibiotics extends to avoiding 
combinations that inhibit each other and may prolong the infection. Antago-
nism, when a drug hinders the effect of another, has been reported early in the 
history of antibiotics and continues to function as a warning against indetermi-
nate treatment [9]. In a study of pneumococcal meningitis patients, 30% of those 
treated with penicillin alone failed treatment and died, while 79% of compara-
ble patients who were treated with the same dosage of penicillin as well as 
chlortetracycline died [10,11]. An increasing number of laboratory studies, 
however, indicate that antagonistic drug combinations as clinical options merit 
more investigation [12].  
While the effects of drug interactions on treatment outcome are well doc-
umented, recent work in this area suggests that the different types of interac-
tions have significant effects on the selection and maintenance of drug re-
sistance mutations. Using a direct competition experiment, Chait and col-
leagues demonstrate how a hyper-antagonistic drug combination is able to se-
lect against a bacterial population resistant to one of the drugs and instead fa-
vor the completely sensitive partner [13]. Aside from influencing competition, 
antagonistic drug combinations may even delay the evolution of resistance. The 
rate of adaptation of laboratory bacteria to multiple drugs has been shown to 
correlate with the degree of synergism between individual antibiotics [14]. Alt-
hough antagonistic drug combinations are currently eschewed in clinical set-
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 tings, these studies suggest that antagonism between antibiotics may aid in de-
vising treatment strategies specifically aimed at delaying the emergence of re-
sistance.  
In response to the slow development of new antimicrobials, there is re-
newed interest in old drugs that have fallen out of use due to toxicity or draw-
backs in efficacy [15]. One suggestion that could be implemented to return these 
drugs to the clinic is to use an old drug in conjunction with a current drug [16]. 
The advantages of synergism and the diverse, non-trivial effects of antagonism 
will play a central role in determining how best to implement combination 
therapy in clinical settings.  
In order to exploit the potential benefits of combination therapy we need a 
better understanding of the circumstances under which synergism versus an-
tagonism is expected.  Determining how a broader spectrum of drugs interact at 
inhibitory concentrations and delineating the mechanisms responsible for these 
effects could allow for a more prudent application of antibiotics that maintains 
clinical capability and does not sacrifice the future utility of these drugs.   
In this study, we ask whether a basic pharmacodynamic property of all 
antibiotics can help predict which pairs would result in antagonism. If bacteri-
cidal drugs are most potent on actively growing cells, then the inhibition of 
growth induced by a bacteriostatic drug should result in a reduction of drug 
efficacy [17,18]. To test this hypothesis, we scour the topology of antibiotic in-
teractions by employing screening methods to identify effects across pairs of 21 
different drugs at sub-inhibitory concentrations. We then take a step towards 
increased clinical relevance by verifying a subset of pairs of interacting drugs at 
inhibitory drug concentrations as time-kill curves. Since our hypothesis relies 
on the decreased antibiotic susceptibility of slowly growing cells and the ability 
of some drugs to influence this state, we repeated our experiments on the level 
of individual cells using time-lapse microscopy in microfluidic devices to inves-
tigate the cellular dynamics underlying combined effects of antibiotics.  
 
Results 
Systematic exploration of interactions between bactericidal and bacteriostatic 
antibiotics 
To quantify interactions between antibiotics, we first selected 21 antibacte-
rial compounds. These antibiotics cover a wide range of mechanisms of action 
and many of them are widely employed in the clinics. Their main targets in-
clude DNA synthesis, translational machinery, cell wall, folic acid, and lipid bi-
osynthesis (Table S1). We systematically measured the effects of all pairs of an-
tibiotics on growth rates of E.coli K12. Specifically, for each pair of antibiotics, 
we combined 6 different concentrations of the agents in a two-dimensional 
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 dose-matrix with dose points being centred on each antibiotic’s half-maximal 
effective concentration (EC50). We considered the Loewe additivity model to as-
sess interactions between antibiotics [19]. In contrast to other models, it 
measures drug-drug interactions based on deviation from a drug-with-itself 
reference. According to the Loewe additivity model, if the modes of action of 
two drugs are the same, they show no interaction. Lines of equal effective dos-
age (isoboles) are represented in the two-dimensional linear concentration 
space of the two drugs. Deviation of these lines from a linear model indicates 
synergism (concave) or antagonism (convex).  We introduced several correction 
steps to overcome potential measurement biases due to plate inhomogeneity, 
and also developed a rigorous statistical framework to assess the significance of 
interactions. Following a previously developed method, we quantified isobole 
shapes by measuring concavity (B), where B=0 indicates independent effects of 
the two drugs (linearity), while B<0 and B>0 indicate antagonism and syner-
gism, respectively (see Methods).  In this work, we focus on studying the prop-
erties of antagonistic antibiotic pairs only, while synergism will be studied 
elsewhere. 
Using a statistical criterion to identify significant interactions (see Meth-
ods), we found that 61% of the 204 antibiotic pairs showed antagonism. The re-
liability of our results was confirmed by comparing to a previous systematic 
drug combination screen performed in E. coli [20]. In spite of the substantial dif-
ferences in the protocols and the underlying assumptions of the models used in 
the two studies, interaction scores are well correlated (Spearman’s rho=0.529, 
P<0.0001) and antagonistic pairs identified in the previous study tend to have 
especially low scores in our screen (Mann-Whitney U-test, P<0.0001). Further-
more, our high-throughput survey correctly identified a well-characterized an-
tagonism between ciprofloxacin and tetracycline [21]. 
The distribution of antagonism is highly non-random on the map of inter-
actions. In line with expectations of the Loewe model, antibiotic pairs that target 
the same cellular subsystem rarely show strong antagonism (P<0.0001). More 
strikingly, combinations of 30S protein synthesis and cell-wall biosynthesis in-
hibitors, 50S protein synthesis and gyrase inhibitors and cell-wall biosynthesis 
and folic acid synthesis inhibitors frequently showed antagonism (P<0.05 for 
each combination, Fisher’s exact test). A common property of these combina-
tions is that a bacteriostatic compound is combined with a bactericidal agent. In 
contrast to bacteriostatic antibiotics that slow or inhibit bacterial growth with-
out causing a substantial short-term population decline, bactericidal antimicro-
bial compounds actively kill bacteria. To minimise the chance of erroneous clas-
sification, we used only E. coli-specific information for bactericid-
al/bacteriostatic classification (Table S1). To more generally test whether antag-
onism is enriched in bacteriostatic-bactericidal combinations, we categorised 
antibiotic pairs according to individual antibiotic killing properties, leading to 
three major groups (cid-cid, cid-stat and stat-stat pairs). Strikingly, we found 
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 that antibiotic pairs with exceptionally low B interaction scores are nearly al-
ways bactericidal-bacteriostatic (Figure 1, P=0.0016, Fisher’s exact test). This re-
sult also holds after excluding antibiotic pairs with overlapping cellular targets 
(P=0.0059). Thus, our data suggests that bacteriostatic agents antagonize the ac-
tion of antibiotics acting on growing cells. This finding is broadly consistent 
with earlier reports demonstrating that growth inhibition via nutrient limitation 
often diminishes the effect of bactericidal compounds [22,23] 
A)  
B)  
Figure 1. Systematic exploration of interactions between bactericidal and 
bacteriostat antibiotics 
A) Heatmap showing pairwise interactions systematically measured be-
tween 21 antibiotics in E. coli. Antibiotics are grouped according to their 
mode of action (see Table 1) and colors reflect the interaction scores between 
them. Negative and positive scores correspond, respectively, to antagonism 
(blue) and synergism (red) according to Loewe additivity criteria. Grey in-
dicates missing data. 
B) Combining a bacteriostatic with a bactericidal antibiotic has a tendency to 
show strong antagonism.  Antibiotic pairs were categorized according to 
their individual antibiotic killing properties leading to three major groups: 
cid-stat, stat-stat, and cid-cid. Antibiotic pairs with lower than -1 interaction 
scores (I,e, those showing strong antagonism) are significantly more likely 
to fall in the bactericidal-bacteriostatic category than the rest of antibiotic 
pairs (p=0.0016, Fisher’s exact test). 59
 Time-kill curves 
The screen for antagonistic and synergistic pairwise interactions was 
based on measuring growth rates, and was thus performed at sub-inhibitory 
concentrations of the antibiotics. To test whether the results of the screen could 
be extrapolated to clinically relevant drug concentrations, we measured death 
rates at inhibitory drug concentrations based on time-kill curves.  We tested 
every possible bactericidal-bacteriostatic pair among five antibiotics across a 
range of concentrations from half to twice their minimum inhibitory concentra-
tion or MIC (Table S2). The antibiotics used in the time-kill experiments were 
selected for their differing mechanisms of action and because to our best 
knowledge, there are no reports of cross-resistance mutations for these drugs in 
E. coli .  
In the presence of a bactericidal drug that alone is capable of clearing a 
bacterial population, the addition of a bacteriostatic drug resulted in a decrease 
in killing rates and a significant number of survivors at the end of the experi-
ment (Figure 2). We also noted that the degree of antagonism differs depending 
on the bactericidal drug employed in the experiment. Acquisition of a resistance 
mutation over the course of the time-kill curve experiment could be a con-
founding effect explaining the reduced death rate observed in bacterial cultures 
treated with a bactericidal-bacteriostatic pair. In order to control for this possi-
bility, the colonies obtained at the end of every time-kill curve experiment were 
replica-plated on antibiotic-containing plates. We found no evidence for the 
evolution of single or multidrug resistance in any replicate to any of the drugs 
used in the experiment (data not shown).  
These time-kill curves provide confirmation that the antagonistic interac-
tion found between drugs at concentrations below the MIC extend to concentra-
tions that rise to inhibitory levels. Furthermore, this interaction manifests as a 
decrease in the rate of killing and the presence of a significant proportion of 
sensitive bacteria at the end of the experiment.  
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Figure 2. Time-kill curves for single and two-drug combinations.  
Each graph shows the time-kill curve for a bactericidal/bacteriostatic drug pair 
and the constituent individual drugs. Error bars represent standard errors of the 
mean for the number of culturable cells, as measured in colony-forming units 
(cfu/mL) at each time point.  
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 Single and combination therapy from the perspective of single cells 
We replicated the conditions of our time-kill curves in a microfluidic de-
vice with the goal of directly observing the effects of different antagonistic drug 
pairs on single cells. Using a device designed to track the elongation and divi-
sion of hundreds of individuals over a long period of time [24], we began by 
growing E. coli cells in rich media without antibiotics for at least four hours to 
determine baseline rates of these cellular processes.  This was followed by ex-
posure to a single drug or pairs of drugs for at least 16 hours. Media were then 
switched back to drug-free broth for at least four more hours.  
By analyzing the resulting time-lapse images, we captured quantitative in-
formation on the rates of cell elongation and division of single cells as they were 
subjected to different antibiotics singly or in antagonistic pairs. Furthermore, 
we followed the fates of hundreds of cells from every condition for viability af-
ter withdrawal of antibiotic-containing media. While every cell exposed to bac-
tericidal drugs either lysed or did not resume growth by the end of the experi-
ment, at least 30% and up to more than 80% of individuals treated with bacteri-
cidal-bacteriostatic drug pairs maintained cellular integrity and resumed divi-
sion after replacement with antibiotic-free media (Table S3).  
We selected at least 20 individual cells per condition for detailed analysis 
using custom software. Figure 3 depicts the lengths of these cells for each condi-
tion across the entire duration of the experiment. The graphs reveal qualitative 
differences in cellular responses to different antibiotic treatments. Our time-
lapse images revealed contrasting responses to the two bacteriostatic drugs tet-
racycline and erythromycin.  As previously reported, we found that tetracycline 
exposure reduced cell elongation and decreased the rate of cell division [21]. 
Erythromycin, however, only reduced the rate of division resulting in filamen-
tous cells that continue to divide. The maximum length depicted in our plots is 
constrained by the length of the growth channel in the microfluidic device – we 
are thus unable to measure the actual size of antibiotic-induced filaments.  
In addition to tracking the rate of elongation of cells in the selected condi-
tions, we also extracted the rates of division of each individual cell as they are 
subjected to different antibiotic-containing media. In Figure 4 we present the 
distributions of the division rates and elongation rates (as cell length doublings 
per hour) for each population in the period of exposure to antibiotics. In order 
to facilitate comparison, data from all cells grown in rich media prior to the ad-
dition of antibiotic is pooled and presented as the “no antibiotic” condition. The 
dashed line on this graph represents the combination of division and elongation 
rates needed to maintain a constant size. Cells to the right of this line, therefore, 
continuously increase in size. This is evident in cells exposed to the two single 
bactericidal antibiotics, nalidixic acid and streptomycin. These drugs primarily 
decreased division rates but did not strongly affect elongation. In contrast, the 
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 single bacteriostatic antibiotics and the paired drugs result in large reductions 
in elongation rate. 
The differences in cellular responses observed in the study of cells ex-
posed to bacteriostatic drugs extend to the results for antagonistic drug pairs. 
Cells treated with tetracycline and either of the bactericidal drugs greatly re-
duced their growth rate and ceased dividing until the antibiotics were with-
drawn while erythromycin paired with a bactericidal drug halted cell division 
resulting in long filamentous cells that only proceeded with division after re-
placement with drug-free media. Our time-lapse microscopy experiments thus 
reveal contrasting responses of bacteria exposed to drugs belonging to the same 
pharmacodynamics class. These differing responses extend to treatment with 
different antagonistic drug pairs.  
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Figure 3. Length-time graphs of individual cells pre/peri/post-antibiotic expo-
sure. 
At least 20 individual cells per antibiotic treatment were selected for analysis us-
ing custom software; the results of each treatment are collated in one graph with 
each line representing the length of a single cell over time. Upward deflections of 
these lines, therefore, denote increases in length and abrupt downward deflec-
tions are division events. This is corroborated with manual inspection of the re-
sulting time-lapse movies. The highlighted section in each graph denotes the pe-
riod in which antibiotic-containing media is used. Lines that end abruptly are due 
to lysis of the cell under observation. The analysis of a population subjected to 
erythromycin alone was problematic due to the formation of long filamentous 
cells that are drawn out of their growth channels as media flows through the 
primary trench of the device – this reduced the number of cells available for ob-
servation over the entire experiment. Furthermore, note that in the erythromycin 
sub-figure, the large fluctuations of cell length denote the increased size to which 
these cells were observed to grow as well as the continuation of division events. 
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Figure 4. The effects of single and paired antibiotics on cell division and elon-
gation.  
We extracted the rates of division and elongation from each of the individual cells 
included in our analysis. Error bars denote the standard errors of the mean. The 
45-degree line in this graph represents the combination of division rate and elon-
gation rate (as doublings of cell length) needed to maintain a constant cell size.  
 
Discussion 
The relevance of classifying antibiotics as bacteriostatic or bactericidal has 
been questioned due to the reliance of these categories on concentration as well 
as on the organism to which it is applied [25]. The manner in which these 
pharmacodynamics properties are used in specific clinical scenarios is beyond 
the scope of this paper. Instead we propose that this binary classification is a 
useful initial step in determining when two drugs in combination would result 
in antagonism and thus should be evaluated to exploit the varied effects of this 
specific interaction.  
The tests set by the Clinical and Laboratory Standards Institute [26] to de-
termine whether an antibiotic is bacteriostatic or bactericidal involve assessing 
the degree of survival of a liquid culture of bacteria after a certain period of 
drug exposure. The moderate killing effect that defines a bacteriostatic agent 
therefore implies an induction of cellular stasis. Here we show that while bacte-
riostatic drugs result in prevalent patterns of antagonistic interactions with bac-
tericidal drugs, their effects on the single cell level may differ considerably. We 
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 found that tetracycline effectively induces stasis in antibiotic-sensitive bacteria. 
We observed this drastic reduction in growth rate and complete arrest of divi-
sion for the entire period of exposure to sub-inhibitory tetracycline. In stark 
contrast, treatment with erythromycin only reduced elongation rate to a similar 
degree as tetracycline however division rates were not as strongly decreased; 
this resulted in long, filamentous cells.   
The differences in morphological response to similarly antagonistic antibi-
otic combinations (Figure 3C) suggest that different cellular mechanisms are 
underlying the increased survival in these pairs of drugs. However, we found 
that adding two different bacteriostatic drugs to a bactericidal drug both result 
in decreased elongation rates. This reduction in rates of elongation could be the 
basis of antagonism. Further work is needed to rule out other potential arbiters 
of this interaction, however our results suggest that the relationship between 
antibiotic killing and cell growth should be disentangled further to consider di-
vision and elongation separately. Determining conditions that specifically affect 
elongation, therefore, could be important in designing strategies that increase 
the efficiency of antibiotic-mediated killing.   
Our results urge caution before forming general assumptions on the ef-
fects of drug interactions. Although our studies of bacteriostatic and bactericid-
al drugs reveal pervasive antagonism on growth and death rates, the variety in 
morphological responses we observe may lead to antibiotic combination-
specific fitness effects. Furthermore the bacteriostatic/bactericidal classification 
system will vary across organisms and the interactions between drugs may sim-
ilarly shift.  Antibiotic combination therapy remains an important viable option 
as a treatment strategy aimed at controlling the rise of resistance. As this goal is 
approached, the single cell dynamics we observed under different antagonistic 
drug pairs highlight the importance of multiple experimental perspectives to 
increase our understanding and predictive power in utilizing drug combina-
tions for more bacterial infections. 
 
Methods 
High-throughput combination screening experiments 
We selected 21 antibiotics that cover a wide range of mechanisms of ac-
tion, including drugs that target cell wall, nucleic acid, protein and folic acid 
biosynthesis (Table 1). Fresh antibiotic solutions were prepared from powder 
stocks on a weekly basis and filter-sterilized before use. All experiments were 
conducted in Escherichia coli K12 (BW25113) in minimal medium supplemented 
with 0.2% glucose and 0.1% casamino acids. Combination screens were per-
formed in 384-well plates using a robotic liquid handling system (Hamilton Star 
Workstation) to improve reproducibility. Culture volume was 50 µl. Each plate 
contained two different 6 x 6 dose-matrix blocks (one antibiotic in combination 
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 with two other antibiotics) in 4 replicates each. For each pair of antibiotics, we 
combined 6 different concentrations of the agents in a serially diluted two-
dimensional dose-matrix with dose points being centred on each antibiotic’s 
half-maximal effective concentration (EC50). The lowest concentration for each 
agent was 0 and the highest was above EC90 (see Table 1). In addition to the 
dose-matrix blocks, each plate included 18 wells containing a medium devoid 
of antibiotics (control wells).  
Antibiotic sensitivity screens were performed by growing cells overnight 
(OD600=4) at 30°C shaken at 300 rpm, diluting until they had an OD equivalent 
to 0.04. Next, using liquid handling robotics, cells were transferred into 384-well 
assay plates (in the presence of antibiotics) to yield 4x104 cells/well. Assay 
plates were incubated at 30°C shaken at 300 rpm for 18h. Bacterial growth was 
monitored by measuring optical density (OD 600) of the liquid cultures at a sin-
gle time point. Preliminary experiments showed that a single reading of optical 
density after 18 hours of incubation shows strong linear correlation with the ar-
ea under the growth curve, a descriptor of overall inhibitory effect that covers 
the entire growth period [27]. Plates were prepared in multiple (up to 6) biolog-
ical replicates and those with quality control issues were omitted from further 
analysis (i.e. growth of control wells was unusually low or showed large varia-
tions, an agent failed to substantially inhibit growth at high concentrations or 
strongly inhibited growth at even low doses). 
 
Data processing and bias correction steps 
To overcome any measurement bias caused by within-plate inhomogenei-
ty, we processed the raw optical density data as follows. We included 18 control 
wells on each plate containing a medium devoid of antibiotics and inoculated 
by E. coli. We used these wells both to set a baseline for zero inhibition and to 
estimate and eliminate within-plate systematic biases. First, we calibrated OD 
values by applying the transformation ODcalibrated = OD + 0.40449*OD3 to account 
for the non-linear association between OD and cell density at high cell densities 
(parameters of the calibration formula were derived as in ref [28]).  Then we 
calculated relative inhibition values based on the initial OD (maximum inhibi-
tion) and the average OD of antibiotic-free control wells (maximum growth). To 
estimate and eliminate within-plate spatial effects, we first fitted a linear trend 
to the control wells to eliminate spatial gradients. Next, for the residuals, we 
employed Gaussian process regression [29] to eliminate the remaining system-
atic spatial biases using the control wells. Both bias correction steps were car-
ried out in MATLAB.  
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 Identifying interacting antibiotic pairs 
To assess antagonism and synergy between pairs of antibiotics we used 
the Loewe additivity model [30], which assumes that a drug does not interact 
with itself. Geometrically, Loewe additivity can be represented as lines of equal 
effective dosage (isoboles) in the two-dimensional linear concentration space of 
the two drugs. Deviation of the shape of isoboles from linearity indicates either 
synergy (concave isoboles) or antagonism (convex isoboles). To identify interac-
tions for each pair of antibiotics, we first merged data from replicate dose-
matrix blocks located on the same 384-well plates. Next, we fitted sigmoidal 
dose response curves (Hill equation) to the single agent responses using a max-
imum likelihood fitting procedure. Based on the single agent response curves of 
the two antibiotics, we calculated the dose response of the combined antibiotics 
expected under the Loewe additivity model. To quantify interactions, we de-
termined the concavity of the set of isoboles inferred from the combination 
measurements for a given antibiotic pair (‘observed’ isoboles). To achieve this, 
we used a mathematical transformation to ‘bend’ the linear isoboles expected 
under the Loewe additivity model to most closely approximate the observed 
isoboles (see Cokol et al. for a similar approach [31]). The transformation relies 
on a single parameter to describe the concavity of the observed isoboles, which 
we use as a measure of antibiotic interaction. This score is zero in the absence of 
interaction, negative for antagonistic and positive for synergistic pairs. Finally, 
interaction score for each antibiotic pair was calculated by taking the median 
score obtained from biological replicates (i.e. independent plates). 
Measurement error of interaction screens was estimated by testing 5 antibiotics 
for interactions with itself in multiple replicates [31]. Because under Loewe ad-
ditivity a drug shows no interaction with itself, deviation of the interaction 
score from zero provides an estimate of the experimental error of interaction 
measurements. Thus, we considered two antibiotics as significantly interacting 
when their score was significantly different from the mean score of self-self an-
tibiotic combinations. 
 
Time-Kill Curves 
Overnight cultures of E. coli MG1655 were diluted 1:10,000 into fresh, pre-
warmed LB broth and incubated for 2 hours. A further 1:2 dilution was per-
formed before introduction into flasks containing either a single or a pair of bac-
tericidal and bacteriostatic antibiotics. These were then incubated with shaking 
and aeration at 37°C. Samples were taken at 1-hour intervals for up to 5 hours. 
Cell densities for each sample were estimated from colony counts by dilution in 
phosphate-buffered saline and plating on LB agar. Each time-kill experiment 
was performed twice.  
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 Time-Lapse Microscopy 
Specific details of the microfluidic system used in this study, the mother 
machine, have been described previously [32].  In brief, this device consists of 
4000 growth channels arranged at right angles against a large trench through 
which growth media is passaged. Nutrients then diffuse into the channels and 
flush out growing cells as they emerge from these channels. An automated mi-
croscope stage allows for the monitoring of multiple fields of view spanning the 
entire device. This method results in the continuous observation of growth and 
division of a large number of individual cells as they experience different anti-
biotic-containing environments and their survival or death after drug has been 
removed.  
Time-lapse microscopy experiments were conducted as follows: E. coli 
MG1655 cultures were grown overnight in LB at 37°C. On the following day, 
100 µL of this culture was diluted in 10 mL of fresh, pre-warmed LB and was 
then incubated with shaking at 37°C for 2 hours. 8 mL of the resulting culture 
was spun down and resuspended in 20 µL of fresh LB. 10 µL of the cell suspen-
sion was then injected into the mother machine; the experiment was initiated 
when more than 80% of the channels were filled with cells via diffusion. A sy-
ringe pump was used to passage fresh LB supplemented with bovine serum al-
bumin (BSA) and salmon sperm DNA through the device at a rate of 2 mL/h. 
Images were acquired from 15-25 fields of view at 6 min intervals via an auto-
mated Olympus BX81 microscope with a UPLFN100xO2PH/1.3 phase-contrast 
oil lens. Samples and the microscope were held at 37°C with a Cube and Box 
incubation system (Life Imaging Services, Reinach, Switzerland). After at least 4 
hours of growth in LB, the media was switched to LB containing BSA, salmon 
sperm, and either single or two antibiotics. Cells were exposed to this regimen 
for at least 20h before being switched back to fresh LB supplemented with BSA 
and salmon sperm DNA for up to 10h. Each experiment consists of fields 
scanned continuously for at least 30h.  
The resulting time-lapse images were then analyzed with a custom-
designed plugin for ImageJ to provide information on cell size and division 
rates during the three different phases of the experiment (available at 
http://projects.exeter.ac.uk/ein/mmj/doku.php). The first step of the analysis 
consists of defining the length of the cell abutting the end of the channel. The 
increasing length of the growing cell over succeeding frames is tracked and rec-
orded; division events are also registered based on cell length. Manual verifica-
tion and annotation were performed after every experiment. In this way, we 
were able to extract quantitative information on an individual cell’s elongation 
and division rates. We also tracked the proportion of cells that survived treat-
ment exposure and were able to divide again upon the return to an antibiotic-
free environment. The occurrence of filamentation during exposure to the anti-
biotics erythromycin and nalidixic acid lead to elongated cells being pulled out 
of their growth channels during flow. For this reason, only channels containing 
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 cells that could be followed for the entirety of the experiment were considered 
in the analysis.  
 
Author contributions 
MA, SB, CP, and PSO conceived and designed the experiments. VL and BB 
performed the pairwise screen of antibiotic interactions. VL and BB analyzed 
the results of the screen, and with CP wrote the corresponding Results and 
Methods section. PSO performed the time-kill curve and microfluidics experi-
ments. PSO, PAzW, M Arnoldini, and SB analyzed the microfluidics data. PSO 
wrote all other sections of the paper. All authors discussed the results and im-
plications and commented on the manuscript. 
 
  
70
 References 
1.  Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment 
protocols to prevent antibiotic resistance. Proc Natl Acad Sci  USA 
94: 12106–12111. 
2.  Hand K (2006) Tuberculosis: Pharmacological Management. 
Hospital Pharmacist 13: 81–85. 
3.  Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) 
Changing patterns of mortality across Europe in patients infected 
with HIV-1. Lancet 352: 1725–1730. 
4.  WHO (2010) WHO Guidelines for the treatment of malaria, Second 
edition. 
5.  Cottarel G, Wierzbowski J (2007) Combination drugs , an emerging 
option for antibacterial therapy. Trends Biotechnol 25: 547–555. 
doi:10.1016/j.tibtech.2007.09.004. 
6.  Forrest GN, Tamura K (2010) Rifampin combination therapy for 
nonmycobacterial infections. Clin Microbiol Rev 23: 14–34. 
doi:10.1128/CMR.00034-09. 
7.  Cunha BA (2004) Therapeutic implications of antibacterial resistance 
in community-acquired respiratory tract infections in children. 
Infection 32: 98–108. doi:10.1007/s15010-004-3065-5. 
8.  Ankomah P, Johnson PJT, Levin BR (2013) The Pharmaco –, 
Population and Evolutionary Dynamics of Multi-drug Therapy: 
Experiments with S. aureus and E. coli and Computer Simulations. 
PLoS Pathog 9: e1003300. doi:10.1371/journal.ppat.1003300. 
9.  Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N 
(2000) Antagonism between penicillin and erythromycin against 
Streptococcus pneumoniae in vitro and in vivo. J Antimicrob 
Chemother 46: 973–980. 
10.  Cates J, Christie R, Garrod L (1951) Penicillin-resistant Bacterial 
Endocarditis Treated by Penicillin and Streptomycin. Brit Med J 1: 
656–656. 
11.  Garrod L (1972) Causes Of Failure In Antibiotic Treatment Garr. Brit 
Med J 4: 473–476. 
71
 12.  Yeh PJ, Hegreness MJ, Aiden AP, Kishony R (2009) Drug interactions 
and the evolution of antibiotic resistance. Nat Rev Microbiol 7: 460–
466. doi:10.1038/nrmicro2133. 
13.  Chait R, Craney A, Kishony R (2007) Antibiotic interactions that 
select against resistance. Nature 446: 668–671. 
doi:10.1038/nature05685. 
14.  Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R (2008) 
Accelerated evolution of resistance in multidrug environments. Proc 
Natl Acad Sci  USA 105: 13977–13981. doi:10.1073/pnas.0805965105. 
15.  Nitzan O, Supornitzky U, Kennes Y, Chazan B, Raz R, et al. (2010) Is 
chloramphenicol making a comeback? IMAJ 12: 371–374. 
16.  Falagas ME, Grammatikos AP, Michalopoulos A (2008) Potential of 
old-generation antibiotics to address current need for new 
antibiotics. Expert Rev Anti Infect Ther 6: 593–600. 
doi:10.1586/14787210.6.5.593. 
17.  Jawetz E, Gunnison J (1953) Antibiotic synergism and antagonism: 
an assessment of the problem. Pharmacol Rev 5: 175–192. 
18.  Jawetz E, Gunnison J, Coleman VR (1954) Observations on the Mode 
of Action of Antibiotic Synergism and Antagonism. J Gen Microbiol 
10: 191–198. 
19.  Loewe S (1928) Die quantitiven Probleme der Pharmakologie. 
Ergebnisse der Physiologie 27: 47–187. 
20.  Yeh P, Tschumi AI, Kishony R (2006) Functional classification of 
drugs by properties of their pairwise interactions. Nature Genetics 
38: 489–494. doi:10.1038/ng1755. 
21.  Bollenbach T, Quan S, Chait R, Kishony R (2009) Nonoptimal 
microbial response to antibiotics underlies suppressive drug 
interactions. Cell 139: 707–718. doi:10.1016/j.cell.2009.10.025. 
22.  Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, et al. (1986) 
Evaluation of the bactericidal activity of beta-lactam antibiotics on 
slowly growing bacteria cultured in the chemostat. Antimicrob 
Agents Chemother 29: 797–802. doi:10.1128/AAC.29.5.797.Updated. 
23.  Eng RHK, Padberg FT, Smith SM, Tan EN, Cherubin CE (1991) 
Bactericidal Effects of Antibiotics on Slowly Growing and 
72
 Nongrowing Bacteria. Antimicrob Agents Chemother 35: 1824–1828. 
doi:10.1128/AAC.35.9.1824.Updated. 
24.  Wang P, Robert L, Pelletier J, Dang WL, Taddei F, et al. (2010) 
Robust Growth of Escherichia coli. Curr Biol 20: 1099–1103. 
doi:10.1016/j.cub.2010.04.045. 
25.  Pankey G, Sabath L (2004) Clinical relevance of bacteriostatic versus 
bactericidal mechanisms of action in the treatment of Gram-positive 
bacterial infections. Clin Infect Dis 38: 864–870. 
26.  Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically; Approved Standard - Seventh Edition. 
Clinical Laboratory and Standards Institute (2006) 
27.  Pena-Miller R, Laehnemann D, Jansen G, Fuentes-Hernandez A, 
Rosenstiel P, et al. (2013) When the most potent combination of 
antibiotics selects for the greatest bacterial load: the smile-frown 
transition. PLoS Biol 11: e1001540. doi:10.1371/journal.pbio.1001540. 
28.  Warringer J, Blomberg A (2003) Automated screening in 
environmental arrays allows analysis of quantitative phenotypic 
profiles in Saccharomyces cerevisiae. Yeast 20: 53–67. 
doi:10.1002/yea.931. 
29.  Carl Edward R, Williams CK (2006) Gaussian processes for machine 
learning. Cambridge, MA: MIT Press. 
30.  Loewe S (1953) The problem of synergism and antagonism of 
combined drugs. Arzneimittelforschung 3: 285–290. 
31.  Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, et al. (2011) 
Systematic exploration of synergistic drug pairs. Mol Sys Biol 7: 544. 
doi:10.1038/msb.2011.71. 
32.  Wang P, Robert L, Pelletier J, Dang WL, Taddei F, et al. (2010) Report 
Robust Growth of Escherichia coli. Curr Biol 20: 1099–1103. 
doi:10.1016/j.cub.2010.04.045.  
 
  
73
  
74
  
 
	  
75
 	  
	  
Figure S1. Length-time graphs of individual cells exposed to streptomycin, and 
streptomycin + tetracycline.  
A) All cells exposed to streptomycin were observed to die during treatment. In 
contrast, a significant number of cells exposed to both streptomycin and tetracy-
cline survived antibiotic exposure. B) These boxplots display the distribution of 
division rates of the cells as they are exposed to either streptomycin, streptomy-
cin and tetracycline, or tetracycline. The division rates of cells in streptomycin 
and tetracycline are not significantly different from the division rates in tetracy-
cline alone.  
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Discussion 
 The problem of antibiotic resistance has evolved from isolated individual 
cases of treatment failure to an insidious epidemic whose scope and magnitude 
are steadily increasing.  The challenge is not just to address the needs of each 
patient but also to determine the environmental factors that influence clinical 
resistance, and to design therapies that delay the evolution of resistance. 
In this dissertation, I argue that the broadening of research focus to in-
clude the period in which bacteria are exposed to antibiotics provides a new 
perspective from which different aspects of this problem could be addressed. 
Here, I expand on issues highlighted by my previous research chapters and dis-
cuss future directions that may help control the spread of clinical resistance. 
Specifically, I draw attention to research foci that pertain to how resistance is 
maintained and spread, and suggest how some bacterial responses to antibiot-
ics could be vulnerabilities that can be exploited. In a final section, I draw on a 
recurring theme across the experimental results I report to propose an alterna-
tive perspective on how the physiological state of antibiotic resistance can be 
viewed.  
 
Antibiotic concentration and population dynamics of sensitive and resistant 
genotypes 
There is increasing evidence suggesting that antibiotics used in hospitals 
and veterinary clinics are entering the environment and impacting the emer-
gence of clinical resistance [1]. Furthermore, it is now recognized that most of 
the mechanisms of resistance adapted by pathogenic bacteria have been im-
ported from the environmental resistome via mobile genetic elements [2]. Alt-
hough evidence is mounting for a link between antibiotic consumption in clini-
cal settings leaking into other areas and environmental bacteria sharing their 
5 
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 resistance genes with pathogens, we can only speculate as to how this link is 
formed, what parameters are important in maintaining this association, and 
whether these relationships can be manipulated to favor sensitive over resistant 
bacteria.  
In Chapter 2, we examine a mechanism by which bacteria are thought to 
commonly reduce the cost of resistance mutations thereby increasing their via-
bility in the absence of drug selection. We help describe when and how com-
pensatory mutations aid the maintenance of resistance by measuring the rela-
tionship between antibiotic concentration and bacterial genotype. In order to 
better predict the population dynamics of resistance emergence, more effort 
should be invested in determining how other mechanisms that spread or sup-
port resistance might vary their effects in relation to different parameters such 
as number, type, and concentration of antibiotics. Two such candidate mecha-
nisms are plasmids and phage.  
Plasmids have long been recognized as an important conveyor of re-
sistance among pathogenic bacteria. These mobile genetic elements are able to 
freely and quickly disseminate themselves across populations of bacteria, and 
even across species of bacteria. Besides facilitating the spread of antibiotic re-
sistance, they can also indirectly maintain other virulence traits by encoding 
mechanisms that maintain the plasmids themselves [3]. These include partition 
systems that operate akin to mitosis and actively segregate plasmids to each 
daughter cell during division, and post-segregational killing systems that kill 
daughters that do not contain a plasmid.  
The diverse mechanisms at the disposal of plasmids have given rise to 
successful, globally disseminated, and increasingly frequent plasmid-mediated 
multidrug resistance. The NDM-1 plasmid is a recent and important example of 
this phenomenon. Originally discovered in an isolate of Klebsiella pneumoniae 
from a patient in New Delhi in 2007, this plasmid has since been reported in 
every continent except Antarctica and South America, and in many species such 
as Escherichia coli, Shigella boydii, Vibro cholera, Acinetobacter, Enterobacteriaceae, 
and in 12 Citrobacter species [4].  
Plasmids have clear, demonstrated effects on the spread of antibiotic re-
sistance. We are, however, unsure of how plasmids acquire resistance genes, 
what factors influence their acquisition, or even in what environments this oc-
curs. The case of NDM-1 serves as an argument for identifying the parameters 
that control the dynamics of a mechanism that spreads and maintains re-
sistance, and not just the resistance mechanism itself.  
Although phage are recognized as important components in shaping the 
ecology of bacteria in the environment, the processes by which they modify the 
human microbiome or human pathogens has not been determined. While some 
phage can enter specific bacterial species and immediately induce lysis, others 
lie dormant by integrating themselves either as a plasmid or directly onto their 
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 host’s chromosome. Bacteria carrying this second, lysogenic type of phage can 
make use of new traits carried on the phage genome – such as antibiotic re-
sistance. Furthermore, the ubiquity of phage in nearly all environments makes 
them particularly suspect in aiding the spread of resistance. Functional meta-
genomic studies revealed a vast array of antimicrobial resistance genes in soil 
bacteria, in phages isolated from environmental samples, as well as in human 
fecal microbiota [5–7]. Lysogenic phage are able to mine this bounty of new 
genes, grant resistance to new hosts they infect, and paradoxically even share 
these traits as they lyse their current host and seek new ones in response to 
stressors such as antibiotics [8].  
As an example, the treatment of the most common genetic disease among 
Caucasians is made complicated by the presence of phage. The ability of phage 
to shuffle the genomes of a bacterial community and generate chimeras better 
adapted to their local environment has been implicated as a significant contrib-
utor to the morbidity of cystic fibrosis (CF) patients [9]. The thick sputum coat-
ing the lungs of patients with CF provide a fertile ground for repeated coloniza-
tion by many bacterial species; treatment, therefore, involves iterative applica-
tion of broad-spectrum antibiotics. Accordingly, examination of the viromes 
isolated from CF patients reveals a significantly more abundant and diverse 
repertoire of resistance genes compared to the viromes from non-CF patients 
[10]. It is likely that antibiotic treatment itself aids in the spread of resistance via 
phage transduction. This provides strong motivation in evaluating the relation-
ship between antibiotic treatment and phage, and how this could be manipulat-
ed to affect the population dynamics of sensitive and resistant bacteria.  
 
Plasticity during antibiotic exposure  
Observations of bacteria undergoing stressors including antibiotic treat-
ment have lead to the recognition of genetic, physiological, and morphological 
plasticity as adaptive responses. Although these mechanisms pose a different 
set of challenges when compared to controlling traditional resistance genes or 
mechanisms, how bacteria respond to antibiotic stress may reveal vulnerabili-
ties that could be exploited to increase the efficacy of a treatment regime.  
Clinically relevant resistance is most often associated with mutations that 
alter the targets of drugs, or dedicated resistance genes such as efflux pumps or 
enzymes that alter the drugs themselves. These mechanisms are inherently cost-
ly since antibiotics are directed at essential genes or functions, or the production 
of pumps or enzymes dedicated to antibiotics result in metabolic costs. Recent 
work has shown how bacteria utilize alternative forms of genetic mechanisms 
to achieve high-level resistance.  
Instead of acquiring a resistance mutation or gene, overproduction of ex-
isting efflux pumps or drug targets has been shown to similarly circumvent a 
wide variety of antibiotics [11]. These genes are amplified via tandem genetic 
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 duplications that have been found to occur in all regions of the chromosome. 
Consequently, this form of resistance presents entirely new challenges. They are 
difficult to identify since the genetic changes they cause are found at the junc-
tions of duplication points and not directly on the genes of interest. Gene dupli-
cations are inherently transient which further complicates their detection and 
study. In addition, whatever costs gene duplications may incur is easily re-
lieved due to their instability.  
Aside from traditional resistance genes, bacterial chromosomes may also 
harbor cryptic resistance genes. These genes are not obviously associated with 
resistance since they are either expressed at low levels or only under certain 
conditions. As an example, poor nutrient conditions resulting in slow growth 
has been found to induce the cryptic aminoglycoside resistance gene, aadA, in S. 
enterica [12]. Since the initiation of this particular type of resistance is contingent 
on growth conditions, this may have significant clinical implications as bacteria 
bearing this gene would pass as aminoglycoside-sensitive under conventional 
susceptibility testing.  
Aside from the genomic architecture that allows for duplications or cryp-
tic genes that manifest only under certain conditions, bacteria have at their dis-
posal an arsenal of morphological traits that allow them to thrive in stressful 
environments. In Chapter 4, we observe the formation of elongated daughters 
in E. coli exposed to some bactericidal antibiotics. Filamentation, or more specif-
ically continued cell growth in the absence of septation, results in organisms 
that are typically 10-50 times longer than their bacillary counterparts and have 
multiple chromosomal copies. Surprisingly, filamentation has been observed 
and implicated as a morphological response resulting in bacterial survival 
against a variety of environmental stresses: including predation by protists, 
host effects during infection, and exposure to antibiotics [13].  
Considering this phenomenon in relation to antibiotic treatment, there are 
two examples in which the induction of filamentation resulted in greater sur-
vival during antibiotic treatment. First, the beta lactam class, antibiotics that in-
terfere with cell wall biosynthesis, induce the SOS response resulting in fila-
mentation. Since beta lactams kill only actively dividing cells, the prevention of 
division accompanying filamentation delays antibiotic-mediated killing [14]. 
Furthermore, the induction of the SOS response augments horizontal transfer of 
DNA, particularly antibiotic resistance elements [15]. In a second example, the 
developmental changes accompanying antibiotic exposure of Burkholderia pseu-
domallei has been found to result in unanticipated protection against unrelated 
antibiotics. In a study linking virulence to antibiotic exposure, Chen and col-
leagues took normal, non-treated B. pseudomallei versus the same strain exposed 
to three different drugs and compared their ability to lyse immortalized im-
mune cells [16]. They found that the bacteria exposed to drugs at or below the 
MIC resulted in filaments with decreased virulence. However, the removal of 
drug permitted the resumption of growth and the production of normal-sized, 
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 bacillary daughter cells. These new cells did not filament during re-exposure to 
drug, were found to be more resistant to new classes of drugs, and were meas-
ured to be as virulent as the untreated control. In this case, while the morpho-
logical response of filamentation is transient and limited to the period during 
which drug is present, the changes induced in the cell are long lasting and pro-
vide additional survival advantages. 
In Chapter 3, I report a novel parallel mechanism by which bacteria may 
circumvent antibiotic stress. I find that exposing streptomycin-resistant bacteria 
to an inhibitory concentration of streptomycin aids the growth of daughter cells 
in a second, unrelated antibiotic. This effect is dependent on both concentration 
and time, as serial transfer of a resistant population grown in antibiotic to a 
drug-free environment does not produce this increased growth effect. Similarly, 
the induction of filamentation we observe in cells exposed to erythromycin in 
Chapter 4 could be involved in the survival of these cells in combination treat-
ment. These two transient phenomena are a few among likely many morpho-
logical and genetic mechanisms utilized by bacteria to withstand killing by an-
tibiotics. As more of these inducible processes are recognized, the justification 
increases for a reevaluation of both the therapeutic regimes that may be condu-
cive for these mechanisms, as well as susceptibility testing that may miss their 
identification.  
 
Increasing the activity of available antibiotics 
In Chapter 4, we argue that combination therapy, the strategy used in con-
trolling resistance in HIV, tuberculosis, and malaria, should serve to inform the 
treatment of more common bacterial infections. While rigorous clinical testing is 
of course required before the standard of care should be altered, we show that a 
basic pharmacodynamic property of all antibiotics is a useful predictor in decid-
ing which pairs of drugs would result in an antagonistic interaction. Such an 
interaction has been shown to influence both treatment efficacy and the evolu-
tion of resistance [17,18]. As resistant infections have increased in frequency, 
many kinds of combination treatments have been suggested as new means in 
tackling pathogens.  
Antibiotic combinations that delay resistance 
While there is an abundance of evidence implicating antagonism between 
antibiotics as a contributor to treatment failure, recent work on this type of in-
teraction raises the possibility of using combinations of drugs to specifically dis-
favor resistant bacteria. Ordinarily, singly resistant mutants are expected to 
have some advantage even in the presence of two drugs. Chait and colleagues 
suggest that this may not be the case if the two drugs in combination result in 
an extreme form of antagonism - suppression [19]. This subclass of antagonism 
is when the combined effect of two drugs is less than at least one of the drugs 
alone. In such an environment, resistance would remove the effect of one drug 
81
 but it would also remove the suppressive interaction. They test their hypothesis 
by competing sensitive and resistant bacteria in either a synergistic or suppres-
sive two-drug matrix. They find specific regions of suppressive drug concentra-
tion combinations that both select against the resistant mutant as well as inhibit 
the wildtype. This raises the prospect of devising treatment regimes that specif-
ically oppose the evolution of resistance. 
 
Antibiotic adjuvants 
Since the 1960s, only three novel antibiotic classes have received approval 
by regulatory agencies, and resistance emerged for one of them even before it 
was put to use in clinics [20]. The scarcity of new treatment options has 
prompted a reappraisal of the currently available drugs and a search for crea-
tive methods by which to increase their clinical utility. In Chapter 4, we take in-
spiration from how resistance is prevented in many chronic diseases and argue 
that using two different antibiotics in combination should be considered in or-
der to achieve the same effect in more common bacterial infections. In addition, 
old drugs that have fallen out of use due to severe side effects or widespread 
resistance can also be resurrected by combining it with an adjuvant. This se-
cond molecule could potentiate the effect of an antibiotic by modifying a cell’s 
physiology to increase susceptibility, or by increasing the concentration of the 
antibiotic within a cell. 
Although the toxic effects of colistin have limited its use, clinics burdened 
with an increase of multidrug resistant Gram-negative bacteria (A. baumanii, P. 
aeruginose, K. pneumoniae) have had little choice but to reintroduce the drug. 
Colistin (polymyxin E) is a cyclic cationic polypeptide antibiotic that permeabil-
ises the outer membrane of Gram-negative bacteria. Recently, scientists have 
shown how combining colistin with a second antibiotic not normally used 
against Gram-negative bacteria, such as rifampicin or vancomycin, can produce 
numerous benefits [21,22]. First, colistin functions in these cases only to perme-
abilise a cell for entry of the second drug and not for its own bactericidal effect; 
this reduces the concentration of colistin needed and reduces the likelihood of 
side effects. Second, the spectrum of the second compound is expanded and re-
sistance is unlikely since this second drug is normally used against a different 
set of bacteria. Furthermore, the synergistic effect of colistin and a second anti-
biotic has been shown to continue even after the emergence of colistin re-
sistance. Colistin increases the permeability of the outer membrane by binding 
to lipid A, a vital component of lipopolysaccharide. Resistance to this drug is 
mediated by mutations in the lpxA gene, which prevent the synthesis of lipid A. 
The consequent impairment of lipopolysaccharide synthesis renders the cell 
hyperpermeable and thus more susceptible to other antibiotics [23]. While 
many examples of inhibitors to multidrug resistance pumps such as AcrAB-
TolC or MexAB-OprM have been isolated from medicinal plants, compounds 
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 with sufficient affinity to many types of clinically relevant efflux has not yet 
been found.  
Aside from increasing the efficacy of an antibiotic by increasing its intra-
cellular concentration, modifying cellular physiology with a second compound 
has been shown to achieve the same effect. This is because many antibiotics 
have been observed to be most effective on dividing or metabolically active 
cells. In Chapter 4, we add to the understanding of how physiology and antibi-
otics are linked by describing how the induction of bacterial stasis can reduce 
killing by these classes of antibiotics. Similarly, cells in a slow-growing persister 
state are protected from this bactericidal class of antibiotics. The reverse, that is 
increasing the effect of an antibiotic by increasing a cell’s metabolic activity, has 
recently been described [24].  
Unlike quinolone or beta lactam drugs that are incorporated as bacteria 
divide, the entry of aminoglycosides relies on proton-motive force that is gener-
ated during metabolism. In seeking to exploit this characteristic, Allison and 
colleagues performed a screen of carbon sources that could aid in the killing of 
dormant cells by increasing their metabolic activity. They found that com-
pounds that enter upper glycolysis (glucose, mannitol, and fructose) potentiat-
ed the in vitro killing of persisters by aminoglycosides. Furthermore, they 
demonstrate the clinical relevance of this strategy by verifying the ability of 
gentamicin and mannitol to treat a biofilm-associated infection in a mouse 
model. While gentamicin alone had no effect, the combination of gentamicin 
and mannitol reduced the number of cells in the biofilm by 1.5 orders of magni-
tude. It is important to note, however, that there was no evidence that mannitol 
or the other effective metabolites lead to the stimulation of division. Their re-
sults demonstrate how a more complete understanding of the role metabolism 
plays in mediating killing by antibiotics could benefit the treatment of recurrent 
infections.  
 
Antibiotic combination therapy can overcome resistance 
Currently, there is only one example of an antibiotic pair that is able to kill 
cells bearing resistance mutations to both drugs. Like the other penicillin anti-
biotics, resistance to oxacillin can be mediated by the production of alternative 
penicillin-binding proteins (PBPs), which are involved in the synthesis of pepti-
doglycan, a major cell wall component. Specifically for oxacillin, the presence of 
this drug induces the expression of the mecA gene and the production of PBP2a. 
In a completely unrelated fashion, vancomycin also targets the cell wall by 
binding to the D-alanine-D-alanine peptide of peptidoglycan precursors and 
preventing their assembly into stable polymers. Resistance to this antibiotic is 
guided by a two-component regulatory system that controls the vanHAX oper-
on, which in turn synthesizes alternative precursors ending in D-alanine-D-
lactate. Interestingly, the unique mechanism of synergy reported for oxacillin 
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 and vancomycin does not occur in sensitive or singly resistant bacteria, but only 
in strains containing both resistance mechanisms. Susceptibility to killing by 
these two drugs is the result of PBP2a being unable to accommodate pepti-
doglycan precursors ending in D-alanine-D-lactate. The simultaneous applica-
tion of both drugs, therefore, induces both the production of PBP2a and the al-
tered peptidoglycan precursor, which results in synergy [25]. 
Although this case will have few if any correlations beyond these particu-
lar antibiotics and mutations, this finding serves as a demonstration for how 
combination therapy can be used to overcome existing multidrug resistance. 
Over the course of this dissertation, I argue that examining the behavior of bac-
teria exposed to antibiotics could lead to strategies that aim for a more attaina-
ble but no less important goal. In order to delay the evolution and spread of re-
sistance, attention should be reoriented to include non-hospital environments 
where pathogens both compete with and benefit from environmental bacteria 
and the vast amount of resistance determinants they harbor. More effort should 
be made to determine the effect of antibiotic concentration on eliciting respons-
es from bacteria, influencing mechanisms of resistance as well as mechanisms of 
their maintenance and spread, and how these relationships impact the popula-
tion dynamics of resistant and sensitive bacteria. Taking inspiration from the 
successful treatment of other diseases such as HIV, combinations of multiple 
drugs or drugs with adjuvants should be reviewed to increase the number of 
available treatment options for more bacterial infections, reduce our dependen-
cy on constant novel drug development, and prolong the useful life of the anti-
biotics we have.  
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 An alternative paradigm on the physiological state of antibiotic resistance: 
Antibiotic resistance only confers resistance to 
killing by an antibiotic.  
There is no contention that antibiotics at varying concentrations induce a 
number of effects in sensitive bacteria. These include changes in fitness (ranging 
from the inhibition of growth, to death), or a wide range of responses (such as 
the morphological changes already discussed in this chapter). However, to the 
best of my knowledge there are no published studies that expressly consider 
antibiotics on the fitness and range of responses of resistant bacteria. A common 
feature in the experimental chapters of this dissertation all indicate that this ar-
ea deserves increased attention.  
In this section, I build upon the relationship of the fitness of resistant bac-
teria and antibiotic concentration that is repeatedly alluded to throughout this 
dissertation. Specifically, I propose that the evolution of antibiotic resistance on-
ly confers resistance to the killing effect of an antibiotic. Bacteria that become 
resistant, therefore, are still susceptible to other effects – genetic, physiologic, 
morphologic, or behavioral – that can be induced by the antibiotic. I consider 
how different mechanisms of resistance may facilitate such antibiotic-induced 
responses in resistant bacteria, how varying concentrations may play a role, and 
even how the location of the resistance determinant (either on the chromosome 
or on a plasmid) may influence this effect. I focus this position on medically rel-
evant resistance in human pathogens, and suggest clinical situations in which 
this phenomenon may play an important role.  
 
Mechanisms of resistance only promote survival in high drug concentrations 
As discussed in greater detail in Chapter 1, the cellular mechanisms that 
confer resistance can be grouped into two broad categories. These are mutations 
of the antibiotic target, or dedicated genes that lower drug concentration (via 
efflux, decreased membrane permeability, or enzymatic inactivation).  
For the first class of resistance mechanisms, cells that are resistant via mu-
tations that affect the binding of an antibiotic to its cellular target may conceiv-
ably “not see” the drug at all. In Chapters 2 and 3, I provide evidence suggest-
ing that this may not always be the case. In both chapters, I utilize bacteria that 
are resistant to streptomycin via mutations on rpsL, a gene that encodes the S12 
subunit of the bacterial ribosome. I show that the fitness of resistant bacteria 
varies according to drug concentration. Furthermore, I found that the presence 
of high streptomycin concentrations could lead to higher growth rates of a 
streptomycin resistant strain in a new antibiotic-containing environment. These 
results support the hypothesis that a strain that has become resistant via mutat-
ing the target of the antibiotic can still be affected by the presence of the drug. 
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 In comparison to resistance mechanisms that lower intracellular concen-
tration, this first group of mutations are found on essential genes and they may 
introduce pleiotropic effects on normal cell physiology (i.e., restrictive strepto-
mycin resistance mutations increase the accuracy of protein elongation). Fur-
thermore, it is also possible that an antibiotic may be able to bind and affect two 
or more different cellular targets. Binding to one of these targets may lead to 
death, while binding to the second target may result in the generation of a dif-
ferent response. The detection of this second response may be masked by the 
death of a sensitive cell. Strains that are resistant via a mutation on the death-
inducing target, however, will not die in the presence of this drug but will still 
have a viable second target by which to produce a second response. Predicting 
the type and variety of responses induced by an antibiotic for this type of re-
sistance determinants, therefore, is likely more difficult.  
In contrast, resistance determinants of the second type may in fact facili-
tate the phenomenon I propose. If we consider two genotypes that only differ 
by the presence of an efflux pump, the resistant strain will survive in high drug 
concentrations by lowering the intracellular antibiotic concentration to below 
the killing threshold. This strain, however, has cellular machinery identical to 
that of the susceptible genotype and is therefore responsive to the presence of 
sub-inhibitory antibiotics.  
 
Determining the role of antibiotic concentration 
A recurring message across the results presented in this dissertation is the 
importance of antibiotic concentration in mediating a number of effects – such 
as producing the non-monotonic dose-response curves of streptomycin re-
sistant Salmonella, or the ability of sub-inhibitory levels of bacteriostatic drugs to 
cause diverse changes in division and elongation rates.  
The model I propose suggests that bacteria that have become resistant do 
not lose the ability to produce responses to sub-inhibitory levels of antibiotic. 
Testing this aspect of the model would be straightforward due to the many 
documented responses of bacteria to low concentrations of drug. As an exam-
ple, the production of cytolethal distending toxin by C. jejuni has been found to 
be potentiated by sub-inhibitory concentrations of erythromycin or ciprofloxa-
cin [26]. Measuring the toxigenic effect of a range of drug concentrations against 
sensitive and resistant C. jejuni could help support this model. 
 
Plasmid-mediated regulatory complexity 
In relation to antibiotic resistance, one of the most recognized features of 
plasmids is their ability to increase the diversity of a bacterial population by fa-
cilitating horizontal transfer and recombination across and between bacterial 
species [27–30]. A complementary role these extra-chromosomal elements play 
86
 is the increased adaptability and responsiveness they confer on their hosts by 
virtue of the variety of genes they carry, as well as the additional regulatory 
complexity they can impose [31,32]. This relationship between the myriad of 
plasmid functions and the signal transduction systems encoded by the plasmid 
to influence both the plasmid itself and the chromosome is a field of intense 
study in a number of pathogens.  
Bacillus anthracis, the Gram-positive, spore-forming agent of anthrax, 
serves as an interesting example to illustrate this point. A virulent strain of B. 
anthracis utilizes two large virulence plasmids, pXO1 and pXO2, that have 
commingled with chromosomal regulatory systems to coordinate its pathogenic 
life history. Infection begins with the inhalation or ingestion of spores. Alt-
hough spores facilitate survival in harsh environmental conditions, the cell 
must transition into a vegetative state to avoid the immune system [33,34]. The 
precise order of signaling events and responsible machinery has yet to be com-
pletely elucidated, but the present knowledge suggests a complicated regulato-
ry network underlies the disease cascade. Chromosomally encoded systems 
that sense cues such as CO2 – bicarbonate (a marker of the mammalian host en-
vironment) or systems that initiate the stress response have been co-opted to 
increase expression of the two essential plasmid-encoded virulence factors, the 
anthrax toxin and capsule [35–37]. Correspondingly, regulators of plasmid ex-
pression have been found to influence the transcription of chromosomal genes 
[38].  
Antibiotic-induced responses may be catalyzed in a similar fashion. A 
plasmid-encoded, two-component regulatory system may respond to the pres-
ence of a drug to express resistance genes, as well as other genes located on ei-
ther the plasmid or the chromosome.  
 
Peeling back the overlapping, interlocking layers of antibiotic resistance 
Antibiotic resistance can be achieved by a variety of genetic and non-
inherited mechanisms. The many genetic changes associated with resistance 
may conceivably constitute only a fraction of the mechanisms responsible for  
bacterial survive in the presence of antibiotics.   
Currently, there are no precise reports on the disease burden attributed to 
non-inherited forms of resistance. Due to the types of pathogens that are known 
to utilize these mechanisms however, it is clear that this number is very large. 
The difficulty in treating infections with M. tuberculosis is primarily due to the 
non-growing, dormant state that reduces the efficacy of antibiotic therapy [39]. 
Behaviors such as swarming, bacterial group motility over a surface, have also 
been implicated in resistance to multiple drugs by pathogens such as Salmonella 
[40]. Pseudomonas aeruginosa exemplifies a perfect storm of effects that all result 
in non-inherited resistance. In this important opportunistic pathogen, regulato-
ry elements have been described that respond to antibiotics to transiently in-
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 crease survival during antibiotic exposure, induce swarming, and the estab-
lishment of a biofilm [41]. As a last example in this non-exhaustive list, the for-
mation of persisters is implicated as the root of recurring infections such as 
those caused by S. aureus [42]. In contrast to resistance, this small subpopulation 
of cells that remain after antibiotic exposure can only resume growth in the ab-
sence of drug and the resulting population is as sensitive as the initial popula-
tion [43].  
It is important to recognize that these different, non-inherited mechanisms 
likely work in concert to promote survival and even lead to genetic resistance. 
Growth in a biofilm has been found to result in endogenous oxidative stress 
that induces double-strand breaks in DNA – genetic diversity is generated 
when these breaks are repaired by a mutagenic mechanism utilizing recombina-
torial DNA repair genes [44]. Interestingly, persistence may also lead to in-
creased diversity and the emergence of genetic resistance [45]. Traditionally 
thought of as a metabolically dormant state, this is now challenged by an in-
creasing amount of evidence suggesting that persistence is initiated and active-
ly maintained by intracellular stress responses [46]. The induction of this stress 
response network can lead to heritable resistance via mutagenesis or the hori-
zontal dissemination of mobile genetic elements bearing resistance genes 
[15,47].  
The paradigm I propose, that antibiotic resistance is only resistance to kill-
ing and that resistant bacteria may still respond to antibiotics in a variety of 
ways, may similarly act in collaboration with different mechanisms that pro-
mote survival during drug exposure. This hypothesis clearly requires rigorous 
experimentation to determine when, to what extent, and in which organisms 
this may exist. What is clear, however, is that many bacterial responses that 
contribute to the virulence and survival of pathogens are only revealed in 
stressful environments. The presence of antibiotics is one such important envi-
ronment. The processes that emerge are closely linked to dynamic regulatory 
networks that coordinate adaptation and ultimately lead to virulence, persis-
tence, and may even foster the evolution of resistance in sensitive members of 
the population. Understanding these responses, therefore, can aid in the identi-
fication of new drug targets and the development of more effective strategies to 
control the problem of antibiotic resistance.   
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